1
Stat
us: Approved,  Date: 14 December 2020Janssen Research & Development *
Clinical Protocol
A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the
Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic
Naïve Subjects with Moderately-to-Severely Active Crohn’s Disease
SEAV
UE: Safety and Efficacy of Adalimumab Versus Ustekinumab for one yEar
Pro
tocol CNTO1275CRD3007; Phase 3b
Amendment 2
Stelara® (ustekinumab); Humira® (adalimumab)
*Janssen Research & Development is a global organization that operates through different legal entities in
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development
studies may vary, such as, but not limited to Janssen Scientific Affairs, LLC; Janssen Biotech, Inc.;
Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen Pharmaceutica
NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen Research & Development, LLC. The term
“sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is
identified on the Contact [CONTACT_12944].
EudraCT NUMBER:    2017-004209-41
Status: Approved
Date: 14 December 2020
Prepared by: [CONTACT_48824], LLC. 
EDMS number: EDMS-ERI-154224669
GCP Compliance: This study will be conducted in compliance with GCP, and applicable regulatory requirements.
Confidentiality Statement
The
 information in this document contains trade secrets and commercial information that are privileged or confidential and
may not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed
by [CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as
privileged or confidential.
[STUDY_ID_REMOVED]
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
2
Ap
proved, Date: [ADDRESS_623839] OF IN-TEXT TABLES AND FIGURES................................................................................................ 5
PROTOCOL AMENDMENTS....................................................................................................................... 6
SYNOPSIS.................................................................................................................................................. 13
TIME AND EVENTS SCHEDULE .............................................................................................................. 17
ABBREVIATIONS...................................................................................................................................... 22
DEFINITIONS OF TERMS.......................................................................................................................... 24
1. INTRODUCTION................................................................................................................................ 25
2. OBJECTIVES, ENDPOINTS , AND HYPOTHESIS........................................................................... 26
2.1. Objectives...................................................................................................................................... 26
2.2. Endpoints....................................................................................................................................... 26
2.3. Hypothes is..................................................................................................................................... 27
3. STUDY DESIGN AND RATIONALE................................................................................................. 27
3.1. Overview of Study Des ign.............................................................................................................. 27
3.2. Study Des ign Rationale.................................................................................................................. 29
3.2.1. Overall Rationale and Endpoints  Chos en for Evaluation ........................................................... 29
4 . PATIENT POPULATION................................................................................................................... 31
4.1. Inclus ion Criteria ............................................................................................................................ 31
4.2. Exclus ion Criteria ........................................................................................................................... 34
4.3. Prohibitions  and Res trictions......................................................................................................... 37
5. TREATMENT ALLOCATION AND BLINDING................................................................................. 37
5.1. Treatment Allocation...................................................................................................................... 37
5.2. Blinding .......................................................................................................................................... 38
6. DOSAGE AND ADMINISTRATION .................................................................................................. 39
7. TREATMENT COMPLIANCE............................................................................................................ 4 1
8. CONCOMITANT THERAPY.............................................................................................................. 4 1
8.1. Concomitant Therapi[INVESTIGATOR_014].................................................................................................................. 41
8.1.1. Crohn’s  Dis eas e-s pecific Concomitant Medications.................................................................. 41
[IP_ADDRESS]. Oral Corticos teroids................................................................................................................. 41
8.2. Prohibited Medications ................................................................................................................... 42
9. STUDY EVALUATIONS.................................................................................................................... 4 3
9.1. Overview........................................................................................................................................ 43
9.2. Efficacy........................................................................................................................................... 44
9.2.1. CDAI ........................................................................................................................................... 44
9.2.2. Video Ileocolonos copy................................................................................................................ 44
9.2.3. Crohn’s  Dis eas e-related Healthcare Utilization.......................................................................... 45
9.2.4. C-reactive Protein and Fecal Calprotectin.................................................................................. 45
9.2.5. PROs.......................................................................................................................................... 45
[IP_ADDRESS]. IBDQ........................................................................................................................................ 45
[IP_ADDRESS]. PROMIS-29............................................................................................................................. 45
[IP_ADDRESS]. WPAI-CD................................................................................................................................. 46
9.3. Pharmacology................................................................................................................................ 46
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
3
Ap
proved, Date: 14 December [ZIP_CODE].3.1. Serum Concentrations  and Antibodies  to Study Agent.............................................................. 46
9.4. Safety Evaluations......................................................................................................................... 46
9.4.1. Advers e Events ........................................................................................................................... 47
9.4.2. Advers e Events  Temporally Related to Infus ion ........................................................................ 47
9.4.3. Injection Site Reactions.............................................................................................................. 47
9.4.4. Clinical Laboratory Tes ts............................................................................................................ 47
[IP_ADDRESS]. Tes ts........................................................................................................................................ 47
[IP_ADDRESS]. Sample Collection and Handling ............................................................................................. [ADDRESS_623840] COMPLETION/DISCONTINUATION OF STUDY TREATMENT/ WITHDRAWAL
FROM THE STUDY........................................................................................................................... [ADDRESS_623841] Quality............................................................................ 66
14 . STUDY DRUG INFORMATION......................................................................................................... 66
14.1. Phys ical Des cription of Study Drug(s )........................................................................................... 66
14.2. Packaging ...................................................................................................................................... 67
14.3. Labeling.......................................................................................................................................... 67
14.4. Preparation, Handling, and Storage............................................................................................... 67
14.5. Drug Accountability........................................................................................................................ 68
15. STUDY-SPECIFIC MATERIALS....................................................................................................... 68
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
4
Ap
proved, Date: [ADDRESS_623842] ................................................... 69
16.2.3. Informed Cons ent....................................................................................................................... 71
16.2.4. Privacy of Pers onal Data............................................................................................................ 71
16.2.5. Long-Term Retention of Samples  for Additional Future Res earch ............................................ 72
16.2.6. Country Selection ....................................................................................................................... 72
17. ADMINISTRATIVE REQUIREMENTS.............................................................................................. 72
17.1. Protocol Amendments .................................................................................................................... 72
17.2. Regulatory Documentation ............................................................................................................ 73
17.2.1. Regulatory Approval/Notification ................................................................................................ [ADDRESS_623843] Identification, Enrollment, and Screening Logs................................................................ 74
17.4. Source Documentation................................................................................................................... 74
17.5. Cas e Report Form Completion ...................................................................................................... 75
17.6. Data Quality As s urance/Quality Control ........................................................................................ [ADDRESS_623844] Retention ........................................................................................................................... 76
17.8. Monitoring ...................................................................................................................................... 76
17.9. Study Completion/Termination....................................................................................................... 77
17.9.1. Study Completion/End of Study.................................................................................................. 77
17.9.2. Study Termination....................................................................................................................... 77
17.10. On-Site Audits................................................................................................................................ 77
17.11. Us e of Information and Publication................................................................................................ 78
REFERENCES............................................................................................................................................ 80
ATTACHMENT 1: SAMPLE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) .......... 82
ATTACHMENT 2:  SAMPLE PROMIS-29 QUESTIONNAIRE.................................................................. 93
ATTACHMENT 3: SAMPLE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT
QUESTIONNAIRE: CROHN’S DISEASE (WPAI-CD)...................................................................... 96
ATTACHMENT 4 :  CROHN’S DISEASE ACTIVITY INDEX...................................................................... 98
ATTACHMENT 5:  STANDARD WEIGHT TABLE.................................................................................... 99
INVESTIGATOR AGREEMENT............................................................................................................... 100
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
5
Ap
proved, Date: [ADDRESS_623845] OF IN-TEXT TABLES AND FIGURES
TABLES
Table 1: Recommended Tapering Schedule for Oral Corticos teroids.................................................... 42
Table 2: Power to detect a treatment effect bas ed on different proportions  of s ubjects  achieving
clinical remis s ion at Week 52 (n=175 each group) ................................................................... 53
FIGURES
Figure 1: Schematic Overview of the Study............................................................................................. 29
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
6
Ap
proved, Date: [ADDRESS_623846] recent amendment.
Amendment 2 (14 December 2020)
The
 overall reason for the amendment: The overall purpose for this amendment is to revise or clarify
secondary, other, and patient-reported outcome (PRO) endpoints for this study, adding Type 1 error control for
major secondary endpoints, updating several secondary endpoints, adding or revising several PRO endpoints, and
clarifying the wording of some endpoints. The added endpoints are to better address patient concerns regarding
treatment of Crohn’s disease, and Health Authority interest pertaining to efficacy. With this amendment, the
updated revisions to the study endpoints will be pre-specified prior to database lock.
More detailed rationales are provided below. Edits to previous text in the protocol are shown in strikeout (for
deleted text) or bold (for added text).
Ap
plicable Section(s) Description of Change(s)
Ra
tionale: Type 1 error control is being added to the analysis of the major secondary endpoints. As a result, they are now
being listed in the order with which they will be hierarchically tested, and one new endpoint is being added which focuses
on the key Crohn’s disease patient symptoms of abdominal pain and diarrhea (ie, stool frequency).
11.3 
Endpoints Added text:
In order to control the overall Type [ADDRESS_623847] major
secondary endpoint will be tested only if the primary endpoint is positive, and the
subsequent endpoint(s) will be tested only if the preceding endpoint in the hierarchy
is positive.
2.2 E
ndpoints; 
11.3.2 Major Secondary 
Endpoints  Added: PRO-2 symptom remission at Week 52 (defined as an abdominal pain
[AP] mean daily score at or below 1 and also stool frequency [SF] mean daily
score at or below 3, ie, AP≤1 and SF≤3) . PRO-2 are the stool frequency and
abdominal pain scores reported as part of the CDAI.
 Moved up to precede endoscopic remission major secondary endpoint:
Clinical remission (defined as CDAI < 150) at Week 16
Ra
tionale: Endpoints pre-specified as “secondary” are being updated to increase emphasis on key patient symptoms of
abdominal pain and diarrhea (ie, stool frequency) and durable response and remission. As the number of these are
intended to be limited in number, some endpoints previously listed as secondary are being moved to “other endpoints”.
11.3.3 
Secondary Endpoints Moved up from Other Endpoints:
 The proportion of subjects with durable clinical remission at Week 52 (defined
as CDAI <150 at Week 52 and at ≥80% of all visits between Week 16 and
Week 52)
11.3.3 
Secondary Endpoints Added:
 The proportion of subjects with durable clinical response at Week 52 (defined
CDAI>100 decrease from baseline at Week 52 and at ≥80% of all visits between
Week 16 and Week 52)
 Absence and/or resolution of AP, defined as a mean daily CDAI AP score of 0
in the week prior to the visit among subjects with mean AP >0 at baseline,
compared at each postbaseline visit through Week 52Pr
otocol Version Date
Original Protocol 11 January 2018
Am
endment 1 27 February 2019
Amendment 2 14 December 2020
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
7
Ap
proved, Date: 14 December 2020 Absence and/or resolution of diarrhea, defined as no loose or watery stools in
the week prior to the visit (ie, SF CDAI sub-score = 0) among subjects with
mean SF >1 at baseline, compared at each postbaseline visit through Week 52
 The proportion of subjects with clinical and biomarker remission, defined as the
proportion of subjects with CDAI<150, CRP <3 mg/L, and also fecal
ca
lprotectin ≤250 µg/g, compared at Weeks 8, 16 and 52
11.3.4
 Other Endpoints,
EfficacyMoved from Secondary to Other Endpoints:
 The change from baseline in SES-CD at Week 52
 The change from baseline in CRP concentration at all postbaseline visits through
Week 52
 The proportion of subjects with normalization of CRP (defined as ≤3 mg/L)
compared at Weeks 8, 16, and 52 among subjects with abnormal CRP (>3 mg/L)
at baseline 
 The change from baseline in fecal calprotectin concentration, compared at
Weeks 8, 16, and 52
11.3.4
 Other Endpoints,
EfficacyRevised analysis:
The change from baseline in the sum of the number of stools and the AP scores in
the prior 7 days, compared individually and combined, without weighting, at all
postbaseline visits through Week 52 (sum of PRO-2)
11.3.4
 Other Endpoints,
EfficacyAdded:
 Maintenance of clinical remission, defined as CDAI<150 at Week 52, among
subjects in remission at Week 16
 Maintenance of clinical response, defined as CDAI decreased at least 100 from
baseline at Week 52 among subjects in response [CDAI decrease at least 100
points from baseline] at Week 16
 The change in the weighted (as per the CDAI) sum of the AP and SF subscores
of the CDAI from baseline at all postbaseline visits through Week 52 (PRO-2
weighted)
 PRO-2 symptom improvement/response, defined as at least a 1 point
improvement (or a mean score of zero) in mean daily CDAI AP score from
baseline, and also a reduction in SF mean daily score of 3 or more (or a mean
score of zero) from baseline, compared at each visit through Week 52
 PRO-2 symptom remission, defined as an AP mean daily score at or below 1 and
a SF mean daily score at or below 3, ie, AP≤1 and SF≤3), compared at each visit
through Week 52
 AP improvement, defined as a 1 point or greater improvement in mean daily
CDAI AP score from baseline, or a mean score of zero, among subjects with
mean AP>0 at baseline, compared at each visit through Week 52
 Reduction in frequency of diarrhea, defined as a reduction of at least 3 (or a
mean number <1) in SF (ie, mean daily number of liquid or very soft stools from
CDAI in the week prior to the visit) from baseline, among subjects with mean
SF >1 at baseline, compared at each visit through Week 52
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
8
Ap
proved, Date: 14 December 2020Rationale: All of the other endpoints that are (or may be) based on fecal calprotectin values were reworded to be more
clear as to the original intent and precise nature of the analyses to be performed, however, there is no change being made
to the planned analyses.
11
.3.4 Other Endpoints, 
EfficacyExample of edits for these endpoints:
 The proportion of subjects with fecal calprotectin ≤ 100 µg/g at all postbaseline
vi
sits through Week 52 at Weeks8, 16, and 52 where fecal calprotectin assessed
am
ong subjects with fecal calprotectin >250 µg/g at baseline
11.3.4
 Other Endpoints, 
EfficacyEdited for clarity:
 The proportion of subjects with fistula resolution (closure of all open/draining
perianal/perirectal fistulas) compared at each postbaseline visit through Week
52 among subjects with one or more open/draining perianal or perirectal fistulas
at baseline
 The proportion of subjects with fistula response (defined as closure of 50% of
open/draining perianal/perirectal fistulas) compared at each postbaseline visit
through Week 52 among subjects with one or more open/draining perianal or
perirectal fistulas at baseline
11.3.4
 Other Endpoints, 
Efficacy Deleted (since narcotic use for reason other than Crohn’s disease is not being
analyzed):
 The proportion of subjects who are on concomitant narcotic pain medications
for any reason
 The proportion of subjects able to eliminate concomitant narcotic pain
medication use for any reason
Ra
tionale: For a number of PRO endpoints based on PROMIS-29 data, the various thresholds for analysis are being revised
to better evaluate the extent of improvement, and the wording of several endpoints is being clarified.
11
.3.4  Other Endpoints, 
PRO EndpointsAdded:
 The change from baseline in the PROMIS-29 domains of Anxiety Score,
Depression Score, Fatigue Score, Pain Interference Score, Sleep Disturbance
Score, Ability to Participate in Social Roles and Activities Score, Physical
Function Score, and Pain Intensity Score compared at Weeks 8, 16, and 52
(results reported separately for each domain)
 The proportion of subjects with a T-score decrease of ≥ 5 in the domains of
Anxiety Score, Depression Score, Fatigue Score, Pain Interference Score, Sleep
Disturbance Score at Weeks 8, 16, and 52 (results reported separately for each
domain)
 The proportion of subjects with a T-score increase of ≥ 5 in the domains of
Ability to Participate in Social Roles and Activities Score, andPhysical Function
Score at Weeks 8, 16, and 52 (results reported separately for each domain)
 The proportion of subjects with a T-score decrease of ≥ 3 in the domains of
Anxiety Score, Depression Score, Fatigue Score, Pain Interference Score, Sleep
Disturbance Score at Weeks 8, 16, and 52 (results reported separately for each
domain)
 The proportion of subjects with a T-score increase of ≥ 3 in the domains of
Ability to Participate in Social Roles and Activities Score, and Physical Function
Score at Weeks 8, 16, and 52 (results reported separately for each domain)
 The proportion of subjects with a score decrease of ≥ ½ baseline standard
deviation in Pain Intensity Score at Weeks 8, 16, and 52
 The proportion of subjects with a T-score decrease of ≥5 in Anxiety Score,
Depression Score, Fatigue Score, Pain Interference Score, Sleep Disturbance
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
9
Ap
proved, Date: 14 December 2020Score and increase of ≥5 in ability to participate in social roles and activities, and
physical function score, at Weeks 8, 16, and 52 
 The proportion of subjects with a T-score decrease of ≥ 3 in Anxiety Score,
Depression Score, Fatigue Score, Pain Interference Score, Sleep Disturbance
Score and increase of ≥ 3 in ability to participate in social roles and
activities, and physical function score, at Weeks 8, 16, and 52 
Ra
tionale: Healthcare resource utilization endpoint being deleted since all relevant analyses have been prespecified, and
this endpoint is not necessary.
He
althcare resource 
utilizationDeleted:
Additional endpoints (not protocol-directed) through Week 52 and based on total
available follow up.
Ra
tionale: Text describing the Actigraphy Substudy is being deleted since there has not been a sufficient number of patients
enrolled in this optional US Substudy to perform any meaningful analyses, and this Substudy was terminated in July 2019
via a letter to the study sites.
Al
l sections related to 
Actigraphy SubstudyDeleted.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
10
Ap
proved, Date: 14 December 2020Amendment 1 (27 February 2019)
The
 overall reason for the amendment: The overall reason for the amendment is to clarify the definition of
endoscopic remission, update the tuberculosis test being used; add instructions for emergency unblinding; and
add a few clarifications.
Ap
plicable Section(s) Description of Change(s)
Ra
tionale: Definition of endoscopic remission is being clarified to allow for subjects enrolled with SES-CD of 3.
Syn
opsis/Endpoints; 
Definitions of Terms; 
2.2 Endpoints; 11.3.2
Major Secondary
Efficacy Endpoints Endoscopic remission (defined as an SES-CD score ≤3 , or = 0 for subjects who enter
the study with an SES-CD =3) at Week 52
Ra
tionale: The tuberculosis test is being updated to include all QuantiFERON-TB tests.
Th
roughout protocol QuantiFERON-TB Gold test
Ra
tionale: CD-related healthcare utilization at screening, which was inadvertently included in the original
protocol, is being removed.
Ti
me and Events 
Schedule, row for
CD-related healthcare
utilizationDeleted at Screening visit.
Ra
tionale:  Text for emergency unblinding is being added per current Sponsor study practices.
Sec
tion 3.2.1, Overall 
Rational and 
Endpoints Chosen for 
Evaluation
(Maintenance of
Blind); Section 5.2,
Blinding; Section
10.2, Discontinuation
of Treatment, 2nd
bulletProcedures to follow for emergency unblinding have been added, following the IWRS
unblinding procedures. These include details for treatment discontinuation and
subsequent follow-up for subjects whose treatment has been unblinded.
Ra
tionale: Since sites are not asked to calculate the SES-CD score at study entry (it is calculated by [CONTACT_485610]), the reference to the SES-CD score is being clarified to avoid confusion at the sites.
4.1 
Inclusion Criteria, 
#4 Has one or more ulceration on screening ileocolonoscopy (which, by [CONTACT_108], would
will result in an SES-CD total score of at least 3 ).
Ra
tionale: Entry requirements pertaining to birth control are recommended to be consistent with local
regulations.
4.1 
Inclusion Criteria, 
#[ADDRESS_623848] agree to use a barrier method of contraception,
consistent with local regulations, ….
Ra
tionale:  The example of an active stoma is being added as an exclusion criterion to reduce confusion as an
active stoma would confound the ability to calculate the CDAI.
4.2
 Exclusion 
Criteria, #[ADDRESS_623849] of ustekinumab or adalimumab treatment using the CDAI, such as:
active stoma; short-gut syndrome and severe or symptomatic strictures or stenosis.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
11
Ap
proved, Date: 14 December 2020Applicable Section(s) Description of Change(s)
Ra
tionale:  For clarity, additional details are being added for hepatitis C testing at study entry.
4.2
 Exclusion 
Criteria, #12 
Time & Events 
Schedule, notes Is seropositive for antibodies to hepatitis C (HCV) without a history of clearance or
successful treatment, defined as being negative for HCV RNA in the past year and, if
treated, at least [ADDRESS_623850] is not eligible for this study.
Screening for HCV to include anti-HCV antibodies. Subjects are eligible if they
are: 1) negative for this test OR 2) positive for anti-HCV antibodies but have a
negative HCV RNA test.
Ra
tionale:  A typographical error in the C-reactive protein units is being corrected.
De
finitions of Terms, 
Normalization of C-
reactive proteinC-reactive protein (CRP) ≤ 3 mug/L
Ra
tionale: Text related to infection details in patient diary cards is being deleted since subjects are not required
to write infection information in their diary cards.
6.  D
osage and 
Administration (last 
paragraph, 2nd 
sentence)Investigators are required to evaluate subjects for any signs or symptoms of infection,
an
d also review subjects’ diary cards for signs of infection, at scheduled visits (see Time
an
d Events Schedule).
Ra
tionale: Text to clarify that a video ileocolonoscopy at any time 3 months prior to randomization is acceptable
is being added.
9.2
.2 Video 
Ileocolonoscopy, 2nd 
sentence; Time and
Events Schedule 
(under Notes) A video ileocolonoscopy recorded during screening and/or within the [ADDRESS_623851] 8 days before the
We
ek 0 visit.
Ra
tionale:  Correction of inadvertent omission regarding hepatitis testing.
9.4
.4.1 Tests, 5th 
bullet  Serology for HIV antibody, HBsAg, anti-HBs, anti-HBc, and hepatitis C virus
antibody
Ra
tionale: Clarification is being made to allow for repeat screening laboratory tests in certain cases.
9.4
.4.1 Tests (last 
paragraph) In some cases it may be medically appropriate to repeat screening laboratory tests if
test values are outside of the required ranges; contact [CONTACT_1034]’s medical monitor
to discuss specific cases.
Ra
tionale: A Legally Acceptable Representative is not allowed per the consenting process since a subject must
be able to participate on their own accord. In addition, wording is being clarified to avoid any confusion with
study entry eligibility, and to allow for Investigators judgment regarding discontinuation for certain cases of
latent TB.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
12
Ap
proved, Date: 14 December 2020Applicable Section(s) Description of Change(s)
10.2, 
Discontinuation 
of Treatment, 4th and 
9th bullets The subject is deemed ineligible to receive further study treatment according
to the following TB screening criteria: 
Note: Consideration for study agent discontinuation Study agent must be
di
scontinued may be given for all subjects diagnosed with latent TB in countries with
hi
gh multidrug-resistant TB burden [eg, South Africa, Bulgaria, and the Russian
Federation]).
 The subject (or the subject’s representative) withdraws consent for further
ad
ministration of study agent.
Ra
tionale: A section heading is being added for “other” endpoints and the previously listed “other secondary”
endpoints were categorized as secondary or other, as appropriate.
11.3 
Endpoints 11.3.3 Other Secondary Endpoints
11.3.4 O
ther Endpoints
Ra
tionale:  Clarification
11.3.4
 Other 
Endpoints, Efficacy 
endpoints at (or 
through) week 52,
24th bulletThe time to first flare (a flare is defined as an increase in CDAI score of > 100 points at
all any subsequent visits through Week 52 [based upon loss of clinical response]) among
su
bjects in clinical response at Week 16
Ra
tionale: Text is being adjusted to reflect that local regulations may require varying return instructions for
study medication.
14.[ADDRESS_623852] be instructed to return all original
containers, whether empty or containing study drug.
Ra
tionale: Language is being updated to remove requirement for dates of birth, to be aligned with EU Privacy
law updates.
17.[ADDRESS_623853] is not randomized into the study, the date seen and age at initial informed
consent date of birth will be used.
Ra
tionale: The cover page footnote is being edited to add the sponsor’s affiliate for Russia.
Cov
er page Janssen Pharmaceutica NV
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
13
Ap
proved, Date: 14 December 2020SYNOPSIS
Title:  A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy
and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naïve Subjects with
Moderately-to-Severely Active Crohn’s Disease
OBJECTIVES, ENDPOINTS, AND HYPOTHESIS
Objectives
The primary objective is to compare the efficacy of treatment with ustekinumab to that ofadalimumab in
biologic naïve subjects with moderately-to-severely active Crohn’s Disease (CD) who have previously
failed or were intolerant to conventional therapy (corticosteroids and/or immunomodulators, ie,
azathioprine, 6-mercaptopurine, or methotrexate), as measured by [CONTACT_485611].
Secondary objectives are to evaluate the following in biologic naïve subjects with moderately-to-severely
active CD treated with ustekinumab or adalimumab:
 Other measures of clinical efficacy (eg, clinical response) including reductions in frequent
concomitant medications associated with adverse outcomes (eg steroids, narcotics)
 Anti-inflammatory efficacy assessed with biomarkers (eg, fecal calprotectin, C-reactive protein)
 Endoscopic endpoints (eg, endoscopic remission)
 Safety (eg, proportions of subjects with serious adverse events, all adverse events, etc.)
 CD-related healthcare utilization (eg, CD-related hospi[INVESTIGATOR_602], surgeries, emergency room
[ER] visits) and the need to initiate another biologic treatment
 Patient Reported Outcome (PRO) assessments such as Inflammatory Bowel Disease
Questionnaire (IBDQ) and Patient Reported Outcome Measurement Information System
(PROMIS), such as quality of life.
Endpoints
The primary endpoint is the proportion of subjects with clinical remission (defined as a Crohn’s Disease
Activity Index [CDAI] score <150) at Week 52.
Major secondary endpoints are the proportion of subjects with:
 Corticosteroid-free remission at Week 52 (defined as a CDAI score < [ADDRESS_623854] 30 days prior to Week 52) 
 Clinical response (defined as a CDAI score decrease ≥100 from baseline) at Week 52
 PRO-2 symptom remission at Week 52 (defined as an abdominal pain [AP] mean daily score at or
below 1 and also stool frequency [SF] mean daily score at or below 3, ie, AP≤1 and SF≤3). PRO-2
are the stool frequency and abdominal pain scores reported as part of the CDAI.
 Clinical remission (defined as CDAI < 150) at Week 16
 Endoscopic remission (defined as an SES-CD score ≤3, or = 0 for subjects who enter the study with
an SES-CD =3) at Week [ADDRESS_623855] previously failed or were
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
14
Ap
proved, Date: 14 December 2020intolerant to conventional therapy (corticosteroids and/or immunomodulators, ie, azathioprine,
6-mercaptopurine, or methotrexate).
OVERVIEW OF STUDY DESIGN
This is a global, randomized, blinded, parallel-group, active-controlled multicenter study. A target of
approximately 350 subjects from up to 200 sites will be randomly allocated in a 1:1 ratio (approximately
175 subjects per treatment arm) to receive study agent (ustekinumab or adalimumab) usingapproved dosing
regimens (specifically, the [LOCATION_002] Prescribing Information [USPI] dosing regimens, which are
incorporated within approved posology in the European Union [EU] and other regions). The target
population consists of subjects with moderately-to-severely active CD of at least 3 months’ duration, with
a CDAI score ≥ 220 and ≤ [ADDRESS_623856] failed
conventional therapy but are biologic naïve.
The study is a superiority study examining rates of clinical remission (ie, CDAI <150) after one year of
treatment (at Week 52).  Study visits are to occur at Screening (within 5 weeks prior to Week 0), and Weeks
0 (baseline), 2, 8, 16, 24, 32, 40, 48, 52 (primary endpoint), and 56, with a final follow-up telephone call
(or on-site, of desired) visit at Week 76.
Study assessments include CDAI and video ileocolonoscopy; CD-related healthcare utilization; PROs
(IBDQ  [Inflammatory Bowel Disease Questionnaire], PROMIS-29 [Patient Reported Outcome
Measurement Information System-29], and WPAI [Work Productivity and Activity Index]); laboratory
evaluations (including hematology, chemistry with C-reactive protein, pregnancy tests, and fecal
calprotectin); biomarkers; physical examinations; vital signs measurements; review of concomitant
medications and adverse events (AEs); and evaluation of serum concentrations of study agent as well as
development of antibodies to study agent.
SUBJECT POPULATION
Subjects are men or women ≥[ADDRESS_623857] 3
months duration, a baseline CDAI score ≥ 220 and ≤ 450, and ulcerations on screening ileocolonoscopy,
and have failed conventional CD therapy or be steroid-dependent for CD, and be biologic naïve. Subjects
with any known malignancy or a history of malignancy or lymphoproliferative disease are to be excluded.
DOSAGE AND ADMINISTRATION
Subjects randomized to ustekinumab will receive a ~6 mg/kg intravenous (IV) induction at Week 0
followed by 90 mg subcutaneous (SC) injections every [ADDRESS_623858] SC
administration occurring at Week 8. Subjects randomized to adalimumab will receive 4 x 40 mg SC
injections at Week 0 (160 mg total), followed by 2 SC injections (80 mg total) at Week 2 and then 40 mg
SC every 2 weeks (q2w) from Week [ADDRESS_623859] been completed, in order to maintain blinding, subjects
will receive medications as follows:
 Group 1 (ustekinumab): An IV infusion of ustekinumab (6 mg/kg) and
4 SC injections of placebo (to blind for adalimumab)
The approximately 6 mg/kg IV infusion of ustekinumab is given in the weight-based fashion shown below,
consistent with labelling:
- 260 mg (weight ≤ 55 kg)
- 390 mg (weight > 55 kg and ≤ 85 kg)
- 520 mg (weight > 85 kg)
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
15
Ap
proved, Date: 14 December 2020 Group 2 (adalimumab): An IV infusion of placebo (to blind for ustekinumab) and
4 SC injections of adalimumab (each 40 mg)
At Week 2, after all study-related procedures have been completed, subjects will receive the following:
 Group 1 (ustekinumab): 2 SC injections of placebo (to blind for adalimumab)
 Group 2 (adalimumab): 2 SC injections of adalimumab (each 40 mg)
All SC study agent administrations at Weeks 0 and 2 will be performed (or supervised) by [CONTACT_485612] (with no other study personnel involved in handling of SC study agent outside of
the carton). At these visits, subjects will be trained to self-administer SC study agent by [CONTACT_485613]. In contrast, the blinded, double-dummy IV
infusion at Week 0 can be administered by [CONTACT_127191].
Beginning at Week 4 (non-visit week) and continuing through Week 56, subjects will self-administer study
agent (generally at home) and will receive:
 Group 1 (ustekinumab): 1 SC injection every 2 weeks (q2w); ustekinumab 90 mg will be
administered every eighth week after Week 0, with placebo for
adalimumab administered at the other designated q2w dosing
intervals
 Group 2 (adalimumab): 1 SC injection of adalimumab 40 mg q2w.
EFFICACY EVALUATIONS
Efficacy evaluations will be based on the results of the CDAI, ileocolonoscopy using the SES-CD scoring
system, C-reactive protein and fecal calprotectin, and questionnaires for PROs (IBDQ, PROMIS-29, and
WPAI-CD). 
PHARMACOKINETIC AND IMMUNOGENICITY EVALUATIONS
Serum samples will be used to evaluate the serum concentrations of ustekinumab and adalimumab, as well
as immunogenicity through assessment of antibodies to both study agents. Serum concentrations and
detection and characterization of antibodies will be determined using validated, specific, drug-tolerant and
sensitive methods by [CONTACT_43754].
SAFETY EVALUATIONS
Safety will be assessed by [CONTACT_485614] 52 or Week 76.
Physical examinations, directed physical examinations (ie, examination for abdominal mass, perianal
fistula, and other fistulas), vital signs, and weight, as well as blood sample collection for serum chemistry
and hematology will be performed.
STATISTICAL METHODS
Sample Size Determination
Th
e assumptions for sample size and power calculations were based on ustekinumab data from completed
Phase 3 studies in the appropriate sub-population of biologic naive CD subjects, as well as in the relevant
anti-tumor necrosis factor (TNF) studies, specifically, the adalimumab Phase 3 CHARM study,7 also
confirmed by [CONTACT_485615] 3b SONIC study,6 which utilized a similar population and design to the
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
16
Ap
proved, Date: 14 December 2020proposed study. Assuming a 41% clinical remission rate at Week 52 in the adalimumab group and 56% in
the ustekinumab group, 175 subjects per treatment group will yield power of approximately 80%, at a
significance level of 0.05 (2-sided Mantel-Haenszel test).
Efficacy Analyses
Fo
r the primary endpoint, the proportion of subjects in clinical remission at Week [ADDRESS_623860], stratified by [CONTACT_485616] 0 (yes or no), baseline
CDAI score (≤ 300 or > 300), and thepresence of ulcerations >5 mmon screening/baseline ileocolonoscopy
(Yes, No) at a significance level of 0.05.
All of the major and other secondary endpoints will be compared between the ustekinumab treatment group
and the adalimumab treatment group using a similar method.
Safety Analyses
Sa
fety will be assessed by [CONTACT_269279], serious adverse events (SAEs), AEs
considered by [CONTACT_1010], probably or very likely related to study agent, AEs leading to
discontinuation of study agent, infections, and injection-site and/or infusion reactions. Safety assessments
will also include analyses of laboratory parameters and change from baseline in laboratory parameters
(hematology and chemistry) and incidence of markedly abnormal laboratory parameters (hematology and
chemistry).
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
17
Ap
proved, Date: 14 December 2020TIME AND EVENTS SCHEDULE
Stu
dy Procedure Sc
reening 
Vi
sit 
(1 
to 5 
we
eks prior
to
We
ek 0) St
udy Visits
(W
eek)a
Ear
ly 
Ter
mb We
ek [ADDRESS_623861] be signed before any study-related activities
are performed.
Co
nfirm inclusion/exclusion
criteria X XEligibility should be reconfirmed at Week [ADDRESS_623862] X Refer to Inclusion Criterion #9for further details.
Ch
est radiograph X An adequate chest radiograph taken within 3
months prior to Week 0 visit may be used (ie, is
sufficient).
Ser
um -hCG pregnancy 
test XTo be performed in females of childbearing
potential.
He
patitis B and C serology X Screening for HBV, at a minimum, to include
HBsAg, anti-HBs, and anti-HBc.  Subjects are
eligible for study if they are: 1) negative for these
tests OR 2) negative for HBsAg; positive only for
anti-HBs; or positive for anti-HBc and surface
antibody OR 3) positive only for anti-HBc, but
with a negative HBV DNA test. Screening for
HCV to include anti-HCV antibodies. Subjects are
eligible if they are: 1) negative for this test OR 2)
positive for anti-HCV antibodies but have a
negative HCV RNA test. See Section 4.2.
HI
V antibody test X Unless negative result in last 3 months is available
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
18
Ap
proved, Date: 14 December 2020Stu
dy ProcedureSc
reening
Vi
sit
(1 
to 5
we
eks prior
to
We
ek 0)St
udy Visits
(W
eek)a
Ear
ly 
Ter
mbWe
ek [ADDRESS_623863] include a stool culture and C. dif f icile
toxin assay performed within 4 months prior to
Week 0. Additional testing, such as ova and
parasite or E. coli O157:H7 assessments, may be
performed at the investigator’s clinical discretion.
Dis
pense CDAI diary and
train subjects regarding
completionXDiary to record CDAI components, concomitant
medications, and at-home study agent
administrations (using adhesive labels from
syringe box/kits).
Ef
ficacy (clinical assessments/CD-related healthcare utilization/PROs)
CD
AI (diary collection) X X X X X X X X X X XCDAI must be calculated at Week 0 for eligibility
(using screening hematocrit value). 
We
ight (component of
CDAI)X X X X X X X X X X X X In Kilograms (Kg)
Vi
deo ileocolonoscopy X X XA video ileocolonoscopy recorded during
screening and/or within the 3 months prior to
randomization may be used. Week 52 procedure
should be perfo rmed ±14 days from Week 52
date. In the e vent that ileocolonoscopi[INVESTIGATOR_485591] 7 days prior, CDAI scores
should be calculated using the proximate 7 days
not impacted by [CONTACT_485617]/or its
preparation.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
19
Ap
proved, Date: 14 December 2020Stu
dy ProcedureSc
reening
Vi
sit
(1 
to 5
we
eks prior
to
We
ek 0)St
udy Visits
(W
eek)a
Ear
ly 
Ter
mbWe
ek 76
Fo
llow-
upc
No
tes0 2 8 16 24 32 40 48 52 56
Fec
al calprotectin X X X X XSamples should not be collected during
ileocolonoscopy preparation. Screening sample
may be provided at Week 0, or when necessary on
different days than study visits (though as close as
possible).
Re
cord CD-related
healthcare utilizationX X X X X X X X X X X XItems to be recorded are listed in the healthcare
resource utilization worksheet.
PRO
s (IBDQ, PROMIS-29,
WPAI)X X X X XAfter randomization, PROs should be conducted
prior to other study-specific procedures.
Saf
ety Procedures
La
boratory Evaluations
He
matology and chemistry,
including CRPX X X X X X X X X X X XLaboratory tests (described in Section 9.4.4) at
Week [ADDRESS_623864] be performed prior to
randomization, to determine eligibility. At all
other visits, perform prior to dispensing study
agent.
Blo
od collection for
evaluation of serum
concentrations and/or anti-
drug-antibodiesX X X X X X XSamples should be collected before study drug
administration.
Blo
od collection for serum
biomarkersX X X X X XSerum biomarkers will be collected from all
participants in the study to assess peripheral
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
20
Ap
proved, Date: 14 December 2020Stu
dy ProcedureSc
reening
Vi
sit
(1 
to 5
we
eks prior
to
We
ek 0)St
udy Visits
(W
eek)a
Ear
ly 
Ter
mbWe
ek 76
Fo
llow-
upc
No
tes0 2 8 16 24 32 40 48 52 56
pr
oteins related to both Crohn’s disease and
response to ustekinumab and adalimumab,
including (but not limited to) IL-17A and IL-22.
Wh
ole blood sample
collection for RNA analysisX X X X XWhole blood for RNA analysis will be collected
from all participants in the study to assess the
RNA transcriptome related to both Crohn’s
disease and response to ustekinumab and
adalimumab.
Ad
ditional Safety Evaluations
Dir
ected Physical Exam at
all visits, with additional Full
Physical Exam where noted
(Full)X
(Full)X X X X X X X X XX
(Full)X
(Full)Directed physical exam for abdominal mass and
fistulas, (perianal and other) at all visits.
Additional full physical exam, including height,
where indicated.
Vi
tal signs X X XVital signs to include temperature, pulse/heart
rate, respi[INVESTIGATOR_697], and blood pressure. Vital
signs to be obtained before, approximately every
[ADDRESS_623865]’s participation in
the study has ended, adverse events should be
followed as described in Section 12.3.
TB
and other infection
assessmentsX X X X X X X X X X X X XAt each visit, site personnel will monitor subjects
for signs or symptoms of TB or other infections.
In addition, subjects will be advised on the risks
of TB and other infectious disease and will be
instructed to monitor themselves on an ongoing-
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
21
Ap
proved, Date: 14 December 2020Stu
dy ProcedureSc
reening
Vi
sit
(1 
to 5
we
eks prior
to
We
ek 0)St
udy Visits
(W
eek)a
Ear
ly 
Ter
mbWe
ek [ADDRESS_623866] should be
performed.
Stu
dy Drug Administration
Dis
pense study agent Xd X X X X X X X X XSC study agent administered with the assistance
ofunblinded site personnel at Weeks 0 and 2.
Thereafter study agent self-administered by
[CONTACT_1766] q2w (generally at home). Study agent
should not be administered if subject is
experiencing a clinically important active
infection. Week 56 study agent to be dispensed
only after Week 52 visit assessments (including
ileocolonoscopy) have been completed and
entered into eCRF. Ifnecessary, subjects may be
unblinded after Week 56 study agent dispensed.
a:
 Study visits should occur at the specified times post-Week 0 +/- 8 days (except Week 2, which should occur +/- 4 days). Note that while visits out of this window should be
documented as a protocol deviation, performing them out of window is preferable to not performing them at all, unless so much time has passed that it is time for the next
visit.
b: To be performed if subjects wish to terminate study participation (eg withdrawing their consent to participate). When subjects discontinue study agent, the early term visit
should be performed 20-[ADDRESS_623867] study agent received, unless they refuse to do so in which case this withdrawal of consent results in performance of this visit at
that time.
c: This visit, which can occur by [CONTACT_648], applies to all subjects, even those who discontinued study agent prior to Week [ADDRESS_623868] otherwise terminated study
participation (eg, withdrawal of consent) unless they specifically do not consent to this telephone follow up from the site.
d: Both IV and SC study agent are administered at Week 0 (baseline) visit. IV infusions (at Week 0) are to be administered over a period of at least [ADDRESS_623869], prior to the Week 0 IV study agent, for operational
efficiency (eg, that way SC injections can be administered after randomization while the IV infusion is prepared). In any case, regardless of whichever treatment is
administered first, it is mandatory that at least [ADDRESS_623870] study agent and initiation of the second.
Key: CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; CRP = c-reactive protein; eCRF = electronic case report form; HBc = hepatitis B virus core; HBs =
hepatitis B surface; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HIV = human immunodeficiency virus; IBDQ = Inflammatory Bowel Disease
Questionnaire; IL = interleukin; IV = intravenous; OTC = over-the-counter; PRO = patient-reported outcome; PROMIS-29 = Patient Reported Outcome Measurement
Information System; q2w; every 2 weeks; SC = subcutaneous; TB = tuberculosis; WPAI = Work Productivity and Activity Index.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
22
Ap
proved, Date: 14 December 2020ABBREVIATIONS
Abbreviation Definition
6-MP 6-mercaptopurine
6-TG 6-thioguinine
-hCG  -human chorionic gonadotropin
AE adverse event
ALT alanine transaminase
AST aspartate transaminase
AZA  azathioprine
BCG Bacille Calmette-Guérin
BUN  blood urea nitrogen
CD  Crohn’s disease
CDAI Crohn’s disease activity index
CRF case report form(s) (paper or electronic as appropriate for this study)
CRP C-reactive protein
eCRF electronic case report form
eDC  electronic data capture
ER  emergency room
EU  European Union
FSH  follicle-stimulating hormone
GCP Good Clinical Practice
GI gastrointestinal
HBc hepatitis B core
HBsAg hepatitis B surface antigen
HBV  hepatitis B virus
HCV  hepatitis C virus
HIV  human immunodeficiency virus
IB  Investigator’s Brochure
IBDQ  Inflammatory Bowel Disease Questionnaire
ICF informed consent form
ICH  International Conference on Harmonisation
IEC  Independent Ethics Committee
IgG1k immunoglobulin G1 kappa
IL Interleukin
IRB  Institutional Review Board
IV  intravenous
IWRS interactive web response system
JAK  Janus kinase
mAb monoclonal antibody
MedDRA  Medical Dictionary for Regulatory Activities
MTX  methotrexate
PFS pre-filled syringe
PQC  Product Quality Complaint
PRO  patient-reported outcome
PROMIS Patient Reported Outcome Measurement Information System
q2w  every 2 weeks
RNA  ribonucleic acid
SAE 
SC serious adverse event
subcutaneous
SES-CD  Simple Endoscopic Score for Crohn’s Disease
S[LOCATION_003]R  suspected unexpected serious adverse reaction
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
23
Ap
proved, Date: [ADDRESS_623871]  upper limit of normal
USPI [INVESTIGATOR_485592]® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
24
Ap
proved, Date: 14 December 2020DEFINITIONSOF TERMS
Term  Definition
Clinical remission CDAI score < 150
Clinical response Decrease in CDAI score of ≥ 100 from baseline
Corticosteroid-free remission CDAI score < [ADDRESS_623872]
30 days prior to Week 52
Corticosteroid-free response Decrease in CDAI score of ≥ [ADDRESS_623873] 3 points
Endoscopic remission 
Endoscopic response 
IBDQ remission SES-CD score ≤3 (or =0 for subjects who enter the study with an
SES-CD =3)
Reduction in SES-CD score by 50% from baseline
Score of > 170
Normalization of C-reactive protein C-reactive protein (CRP) ≤ 3 mg/L (among subjects with abnormal
CRP at baseline)
Perianal/perirectal fistula healing Complete closure of perianal/perirectal fistulas present at baseline
Time to first flare Time to an increase in CDAI score of >100 points
Women of non-childbearing potential Women ≥[ADDRESS_623874] 18 months or
hysterectomy or tubal ligation, or ≥[ADDRESS_623875] 6 months and a serum follicle-stimulating hormone (FSH)
of > 40 IU/mL
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
25
Ap
proved, Date: 14 December [ZIP_CODE]. INTRODUCTION
Ustekinumab is a fully human immunoglobulin (IgG)1k monoclonal antibody (mAb) to human
Interleukin (IL)-12/23p40 that binds with high affinity to human IL-12 and IL-23. Ustekinumab
prevents IL-12 and IL-23 bioactivity by [CONTACT_485618]-12Rβ1
receptor protein. Through this mechanism of action, ustekinumab effectively neutralizes all IL-12
(Th1) and IL-23 (Th17) mediated cellular responses tested using in vitro bioassays. Abnormal
regulation of IL-12 and IL-23 has been associated with multiple immune-mediated diseases,
including inflammatory bowel disease, and binding the IL 12/23p40 subunit provides effective
therapy in Crohn’s disease (CD).
Ustekinumab has been approved for multiple indications for immune-mediated diseases. It has
been approved in multiple countries for the treatment of patients with moderately-to-severely
active CD who:
 Have failed or were intolerant to treatment with immunomodulators or corticosteroids, but
never failed a tumor necrosis factor (TNF) blocker, or
 Have failed or were intolerant to treatment with one or more TNF blockers.21
In both populations, treatment was effective for both induction of response at 6 weeks and
remission at 8 weeks as well as maintenance of remission and response after a total of one year of
treatment.10
Adalimumab is a recombinant human IgG1 mAb that binds specifically to human TNFα. This
binds soluble TNF, blocking interaction with the p55 and p75 cell surface TNF receptors. It also
binds cell surface TNF. Adalimumab has multiple indications for immune-mediated diseases.
Adalimumab has been approved for moderately-to-severely active CD in patients who (per the
[LOCATION_002] Prescribing Information [USPI]).17
 Are naïve to TNF blockers,
 Have had an inadequate response to conventional therapy, or
 Have lost response to, or were intolerant of, infliximab.
Adalimumab is also approved for maintenance of clinical remission.
While both ustekinumab and adalimumab are approved and widely used to treat CD, it is not
known whether one offers superior clinical results than the other.  Comparison of results from
previously published trials suggest similar results in induction, but lower response and remission
rates in biologic naïve subjects treated with adalimumab maintenance compared to biologic naïve
subjects treated with ustekinumab. However, indirect comparisons across studies are problematic
due to different study designs, endpoints, populations, and other factors.  Since these medications
have not been evaluated in a head-to-head trial, this represents an important gap in the scientific
literature important for evidence-based practice. This study will fill this gap by [CONTACT_1541] a
prospective, randomized direct comparison of one year of treatment with ustekinumab and
adalimumab, evaluating efficacy and safety in biologic naïve subjects with Crohn’s disease who
have failed conventional therapy.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
26
Ap
proved, Date: 14 December 2020Note that the term "sponsor" used throughout this document refers to the entities listed in the
Contact [CONTACT_23774](s), which will be provided as a separate document.
2. OBJECTIVES , ENDPOINTS, AND HYPOTHESIS
2.1. Objectives
Primary:
To compare the efficacy of treatment with ustekinumab or adalimumab in biologic naïve subjects
with moderately-to-severely active CD  who have previously failed or were intolerant to
conventional therapy (corticosteroids and/or immunomodulators, ie, azathioprine [AZA],
6-mercaptopurine [6-MP], or methotrexate [MTX]), as measured by [CONTACT_485611].
Secondary :
To evaluate the following in biologic naïve subjects with moderately-to-severely active CD treated
with ustekinumab or adalimumab:
 Other measures of clinical efficacy (eg, clinical response) including reductions in frequent
concomitant medications associated with adverse outcomes (eg steroids, narcotics)
 Anti-inflammatory efficacy assessed with biomarkers (eg, fecal calprotectin, C-reactive
protein)
 Endoscopic endpoints (eg, endoscopic remission)
 Safety (eg, proportions of subjects with serious adverse events, all adverse events, etc.)
 CD-related healthcare utilization (eg, CD-related hospi[INVESTIGATOR_602], surgeries, emergency room
[ER] visits) and the need to initiate another biologic treatment
 Patient-reported outcome (PRO) assessments, such as Inflammatory Bowel Disease
Questionnaire (IBDQ) and Patient Reported Outcome Measurement Information System
(PROMIS).
2.2. Endpoints
Primary Endpoint:
The proportion of subjects with clinical remission (defined as a Crohn’s Disease Activity Index
[CDAI] score < 150) at Week 52.
Major Secondary Endpoints:
The proportion of subjects with:
 Corticosteroid-free remission at Week 52 (defined as a CDAI score < [ADDRESS_623876] 30 days prior to Week 52) 
 Clinical response (defined as a CDAI score decrease ≥100 from baseline) at Week 52
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
27
Ap
proved, Date: 14 December 2020 PRO-2 symptom remission at Week 52 (defined as an abdominal pain [AP] mean daily score
at or below 1 and also stool frequency [SF] mean daily score at or below 3, ie, AP≤1 and
SF≤3)
 Clinical remission (defined as CDAI < 150) at Week 16
 Endoscopic remission (defined as an SES-CD score ≤3, or SES-CD =0 for subjects who enter
the study with an SES-CD =3) at Week 52
Other Endpoints: Refer to Section 11.3.[ADDRESS_623877] of all other endpoints.
2.3. Hypothesis
Ustekinumab is superior to adalimumab as measured by [CONTACT_485619] (ie, at the Week 52 visit) in biologic naïve subjects with moderately-to-severely active
CD who have previously failed or were intolerant to conventional therapy (corticosteroids and/or
immunomodulators).
3. STUDY DESIGN AND RATIONALE
3.1. Overview of Study Design
This is a global, randomized, blinded, parallel-group, active-controlled multicenter study. A target
of approximately 350 subjects from up to 200 sites will be randomly allocated in a 1:1 ratio
(approximately 175 subjects per treatment arm) to receive study agent (ustekinumab or
adalimumab) using on-label, approved dosing regimens described further below. The study is a
superiority study examining rates of clinical remission (ie, CDAI <150) after one year of treatment
(at Week 52).
The target population consists of men or women ≥[ADDRESS_623878] 3 months’ duration, with a CDAI score of ≥ 220
and ≤ [ADDRESS_623879] not previously received biologic
therapy (ie, are biologic naïve) and who have failed conventional therapy. For a full list of entry
criteria, see Section 4.
Study visits are to occur at Screening (within 1- 5 weeks prior to Week 0), and Weeks 0, 2, 8, 16,
24, 32, 40, 48, 52 (primary endpoint), and 56, with a final follow-up telephone call (or on-site visit,
if preferred) at Week 76.
At Week 0, after all study-related procedures have been completed, subjects will receive the
following:
 Group 1 (ustekinumab): An intravenous (IV) infusion of ustekinumab (approximating
6 mg/kg per weight-based dosing) and 4 subcutaneous (SC)
injections of placebo for adalimumab
 Group 2 (adalimumab): An IV infusion of placebo for ustekinumab and
4 SC injections of adalimumab (each 40 mg)
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
28
Ap
proved, Date: 14 December 2020IV infusions (at Week 0) are to be administered over a period of at least [ADDRESS_623880], prior to the Week 0 IV study agent, for operational efficiency (eg, that way SC
injections can be administered after randomization while the IV infusion is prepared). In any case,
regardless of whichever treatment is administered first, it is mandatory that at least [ADDRESS_623881] been completed, subjects will receive the
following:
 Group 1 (ustekinumab): 2 SC injections of placebo
 Group 2 (adalimumab): 2 SC injections of adalimumab (each 40 mg)
All SC study agent administrations at Weeks 0 and 2 will be performed (or supervised) by [CONTACT_485620] (see Section 6). At these visits, subjects will be trained to self-
administer SC study agent by [CONTACT_485621]. The blinded, double-dummy IV infusion at Week 0 can be administered by
[CONTACT_127191].
Beginning at Week 4 (non-visit week) and continuing through Week 56, subjects will self-
administer study agent, generally at home, and will receive:
 Group 1 (ustekinumab): 1 SC injection every 2 weeks (q2w); ustekinumab 90 mg will
be administered every eighth week after Week 0, with placebo
for adalimumab administered at the other designated q2w
dosing intervals
 Group 2 (adalimumab): 1 SC injection of adalimumab 40 mg q2w.
Study assessments include CDAI, video ileocolonoscopy; CD-related healthcare utilization (eg,
CD-related hospi[INVESTIGATOR_602], surgeries, ER visits, initiation of biologic treatment outside of that
provided by [CONTACT_990]); PROs (Inflammatory Bowel Disease Questionnaire [IBDQ], Patient
Reported Outcome Measurement Information System [PROMIS]-29, and Work Productivity and
Activity Index [WPAI]); laboratory evaluations (including hematology, chemistry with CRP,
pregnancy tests, and fecal calprotectin); biomarkers; physical examinations; vital signs; weight,
review of concomitant medications and adverse events (AEs); and evaluation of serum
concentrations of study agent as well as development of antibodies to study agent.
A diagram of the study design is provided in Figure 1 .
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
29
Ap
proved, Date: 14 December 2020Figure 1: Schematic Overview of the Study
R Ustek
inumab 6mg/kg* IV at week 0 and 90 mg SC Q8wk
* Ustekinumab 260 mg (weight ≤ kg
Ustekinumab 390 mg (weight > 55 kg and ≤85 kg)
Ustekinumab 520 mg (weight > 85 kg)
(N=175)(N=175)
Adalimumab 160 mg SC at week 0, 80 mg SC at week 2 and 40 mg SC Q2wk 
Week 52 -5 40 24 32 16 0 48 
R PE S 
C C
C = Colonosco
py      Corticosteroid tapering, if applicable, to have begun at Week 8-16S = Scr
eening R = R andomization PE = Primary Endpoint76 2 8 56 
3.2.
 Study Design Rationale
3.2.1. Overall Rationale and Endpoints Chosen for Evaluation
Crohn’s disease is an autoimmune disorder causing significant symptoms as a result of gut
inflammation, which may affect the entire gastrointestinal (GI) tract as well as multiple other organ
systems. It is a chronic disease that has a progressive course resulting in both penetrating and
fibrotic complications.  As many as 70% of patients with CD will develop complications, many of
whom will require surgical management during their lifetime, often including multiple bowel
resections.[ADDRESS_623882] of patients treated with anti-TNF antibodies do
not respond to these agents and of those who do respond, 30-40% lose response within the first
year.18,24
Two Phase 3 pi[INVESTIGATOR_6518], UNITI-1 (CNTO1275CRD3001) and UNITI-2
(CNTO1275CRD3002), evaluated response and remission after induction with IV ustekinumab.[ADDRESS_623883] trial enrolled subjects who had failed or were intolerant to TNF blockers, while the second
enrolled subjects who had failed conventional therapy but not anti-TNF agents.  In UNITI-2, the
majority of subjects (~2/3) were anti-TNF naïve with the remaining (~1/3) having been exposed
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
30
Ap
proved, Date: 14 December 2020to but not failed any of these medications. A total of59% of these subjects in UNITI-2 responded
to induction with IV ustekinumab after 8 weeks.
Subjects who responded to IV ustekinumab at Week 8 of these induction studies then entered the
IM-UNITI (CNTO1275CRD3003) maintenance study in the primary efficacy population, and
underwent randomized withdrawal for 44 more weeks, and were randomized 1:1:[ADDRESS_623884] failed TNF blockers is unknown, but could be due to somewhat shorter disease
duration and/or severity seen in the TNF blocker naïve patient population. Among anti-TNF-naïve
subjects who had responded to induction treatment, 65% were in remission after a total of [ADDRESS_623885] an anti-drug antibody
incidence of <3%, using a newer drug tolerant, high sensitivity assay. This likely means that the
practice of adding an immunomodulator such as AZA, 6-MP, or MTX that is common with
infliximab likely is neither necessary or helpful. Ustekinumab also has an acceptable safety profile,
with a long history of use in psoriasis, having been first approved in 2009, complementing the
more recent approvals in CD in 2016.
Response of subjects with CD to induction with adalimumab in TNF blocker-naïve subjects was
demonstrated with the CLASSIC I study12 and a maintenance phase for these subjects was
evaluated in the CLASSIC II trial, albeit with arelatively small number of subjects.[ADDRESS_623886] trial,
CHARM,7 was performed in which subjects were given open-label induction with adalimumab
and responders entered a randomized withdrawal study where they were randomized 1:1:1 to
receive adalimumab SC 40 mg every other week, 40 mg every week, or SC placebo. A total of
41% of induction responder anti-TNF naïve subjects treated with adalimumab [ADDRESS_623887] failed conventional therapy
(consistent with labelling of both agents). Generating comparative efficacy data will allow
development of more informed, evidence-based treatment strategies for patients with potentially
progressive and high morbidity disease.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
31
Ap
proved, Date: [ADDRESS_623888] dosing of the TNF blocker,
adalimumab, with the anti-IL12/[ADDRESS_623889] attributes (eg, demographic and baseline
characteristics) are evenly balanced across treatment groups, and enhance the validity of statistical
comparisons across treatment groups, and will be performed 1:[ADDRESS_623890] been completed and entered into the electronic case report form (eCRF). In
the event of an emergency, the investigator may also unblind a subject’s treatment if such
knowledge would change the subject’s clinical care (see Section 5.2).
There will be a second database lock after the last subject has completed his or her Week 76
visit/interaction.
Healthcare Resource U tilization
Data pertaining to, eg, CD-related hospi[INVESTIGATOR_602], surgeries, ER visits, medication use, and
physician visits will be used to evaluate healthcare resource utilization, which are important
considerations when assessing ideal therapy selection in CD patients.
[ADDRESS_623891] meet the following criteria to be enrolled:
1. Be male or female (according to their reproductive organs and functions assigned by
[CONTACT_379657]) ≥[ADDRESS_623892] 3 months’ duration, with colitis, ileitis, or ileocolitis,
confirmed at some time in the past by [CONTACT_485622], histology, and/or endoscopy.
3. Has moderately-to-severely active CD with a baseline CDAI score of≥ 220 and ≤ 450.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
32
Ap
proved, Date: 14 December [ZIP_CODE]. Has one or more ulceration on screening ileocolonoscopy (which, by [CONTACT_108], would result
in an SES-CD  of at least 3).
Note:  If a subject had an ileocolonoscopy but then screen failed for another reason, if he/she
is rescreened within 3 months, then that ileocolonoscopy is sufficient for inclusion if all other
entry criteria are met.
5. Meets the following requirements for prior or current medications for CD:
a) Has failed conventional therapy:
i) Is currently receiving corticosteroids and/or immunomodulators (ie, AZA, MTX, or
6-MP) at adequate therapeutic doses;
OR
ii) Has a history of failure to respond to, or tolerate, an adequate course of corticosteroids
and/or immunomodulators (ie, AZA, MTX, or 6-MP);
OR
            iii) Is corticosteroid dependent or has a history of corticosteroid dependency;
AND
b) Has not previously received an approved biologic for CD (ie, infliximab, adalimumab,
certolizumab pegol, ustekinumab, natalizumab, vedolizumab or approved biosimilars of
these agents).
6. Subjects on oral corticosteroids (eg, prednisone, budesonide) at a prednisone-equivalent dose
of 40 mg/day or  9 mg/day of budesonide are permitted provided doses meeting these
requirements are stable for 3 weeks prior to baseline (Week 0) or these have been discontinued
at least 3 weeks prior to baseline.
7. Subjects on the immunomodulators AZA, 6-MP, or MTX at screening (or recently prior),
must discontinue these medications at least [ADDRESS_623893] results within the following parameters:
a) Hemoglobin: 8.5 g/dL
b) White blood cells (WBC): > 3.5 x 103/µL
c) Neutrophils: >1.5 x 103/µL
d) Platelets: > 100 x 103/µL
e) Serum creatinine: < 1.7 mg/dL
f) Aspartate transaminase (AST) and alanine transaminase (ALT) concentrations:
Within [ADDRESS_623894].
g) Direct (conjugated) bilirubin: < 1.0 mg/dL.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
33
Ap
proved, Date: 14 December [ZIP_CODE]. Is considered eligible per the following tuberculosis (TB) screening criteria:
a) Has no history of latent or active TB prior to screening; exceptions are made for a subject
who:
 Is currently receiving treatment for latent TB without evidence of active TB (or has
initiated treatment for latent TB prior to Week 0 study agent administration)
 Has a history of latent TB and documentation of having completed adequate
treatment for latent TB within [ADDRESS_623895] administration of study agent. 
It is the responsibility of the investigator to verify the adequacy of previous TB treatment
and provide/obtain appropriate documentation.
b) Has no signs or symptoms suggestive of active TB upon medical history and/or physical
examination.
c) Has had no recent, known close contact [CONTACT_4490] a person with active TB or, if there has been
such contact, the subject is to be referred to a physician specializing in TB to undergo
additional evaluation and, if warranted, receive appropriate treatment for latent TB prior
to, or simultaneously with, the first administration of study agent.
d) Within [ADDRESS_623896] administration of study agent, either has:
 A negative QuantiFERON-TB test, or
 Anewly identifiedpositive QuantiFERON-TB test in which active TB has been ruled
out and for which appropriate treatment for latent TB has been initiated either prior
to, or simultaneously with, the first administration of study agent. 
A subject whose first QuantiFERON-TB test result is indeterminate should have the test
repeated. In the event that additional QuantiFERON-TB test result is persistently
indeterminate, the subject should also initiate treatment for latent TB in order to enter the
study. 
The QuantiFERON-TB In-Tube test is not required at screening for subjects with a
history of latent TB and appropriate treatment as described above. 
e) Has a chest radiograph (at least a posterior-anterior view), taken within [ADDRESS_623897] be:
a) Postmenopausal, defined as
i) ≥ [ADDRESS_623898] 18 months,
OR
ii) ≥ [ADDRESS_623899] 6 months and a serum FSH level
> 40 IU/mL
OR
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
34
Ap
proved, Date: 14 December 2020b) Of childbearing potential, in which case she must satisfy at least one of the below:
i) Surgically sterile (has had a hysterectomy or bilateral oophorectomy, tubal ligation, or
otherwise be incapable of pregnancy), or
ii) If heterosexually active, practicing a highly effective method of birth control, including
hormonal prescription oral contraceptives, contraceptive injections, contraceptive
patch, intrauterine device, double-barrier method (eg, condoms, diaphragm, or cervical
cap, with spermicidal foam, cream, film, gel or suppository), or male partner
sterilization, consistent with local regulations regarding use of birth control methods
for subjects participating in clinical trials, for a period of [ADDRESS_623900]
administration of study agent,
or
iii) Not heterosexually active.
Note:  If a woman participant’s childbearing potential changes after start of the study (eg,
a premenarchal woman experiences menarche) or if women of childbearing potential
who are not heterosexually active at screening become heterosexually active, they must
agree to utilize a highly effective method of birth control, as described above.
11. Female participants of childbearing potential (menstrual and not surgically sterile), must have
a negative serum beta-human chorionic gonadotropin ( -hCG) pregnancy test at screening
and a negative urine pregnancy test at Week 0 (prior to randomization) and agree not to donate
eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period
of [ADDRESS_623901] agree to use a barrier method of contraception, consistent with
local regulations, (eg, condom with spermicidal foam/gel/film/cream/suppository) and to not
donate sperm during the study and for [ADDRESS_623902] study agent administration.
13. Sign an informed consent document indicating that he/she understands the purpose of, and
procedures required for, the study and are willing to participate in the study.
[ADDRESS_623903] who meets any of the following criteria may not be enrolled in the study:
1. Has complications of CD that are likely to require surgery or would confound the ability to
assess the effect of ustekinumab or adalimumab treatment using the CDAI, such as: active
stoma; short-gut syndrome and severe or symptomatic strictures or stenosis.
2. Currently has, or is suspected to have, an abscess. Recent cutaneous and perianal abscesses
are not exclusionary if drained and adequately treated at least 3 weeks prior to baseline, or
8 weeks prior for intra-abdominal abscesses, if there is no anticipated need for any further
surgery.  Subjects with active fistulas may be included if there is no anticipation of a need for
surgery and there are currently no abscesses present.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
35
Ap
proved, Date: 14 December [ZIP_CODE]. Has had any kind of bowel resection within 6 months prior to baseline or other intra-abdominal
surgery or a hospi[INVESTIGATOR_485593] 3 months prior to baseline.
4. At any time received any monoclonal antibody (including biosimilars) targeting TNFα, IL-12,
or IL-23, or anti-integrin agents approved for CD (ie, vedolizumab or natalizumab) or has
received any of the following medications or therapi[INVESTIGATOR_485594]: 
a) Any other investigational agent for CD (eg other biologics, small molecules or anti-sense
RNA such as mongersen), unless at least [ADDRESS_623904]
dose.
b) IV corticosteroids as a treatment for CD < 3 weeks prior to baseline.
c) Oral immunomodulatory agents other than AZA, 6-MP, or MTX (eg, Janus kinase [JAK]
inhibitors, 6-thioguanine [6-TG], cyclosporine, tacrolimus, sirolimus, tofacitinib, or
mycophenolate mofetil) < 4 weeks prior to baseline.
(Note that per inclusion criterion 7, typi[INVESTIGATOR_485595] [AZA, 6-MP or
MTX] must have been discontinued at least 3 weeks prior to baseline.)
d) Treatment with apheresis (eg, Adacolumn apheresis) or total parenteral nutrition (TPN)
as a treatment for CD < [ADDRESS_623905] 4 months unless a repeat examination is negative and
there are no signs of ongoing infection with that pathogen.
6.
 Has received a Bacillus Calmette–Guérin (BCG) vaccination within [ADDRESS_623906] infection (eg,
recurrent pyelonephritis or chronic nonremitting cystitis), or infected skin wounds or ulcers.
8. Has current signs or symptoms of infection, or recent (within 8 weeks prior to baseline) history
of herpes zoster or serious infection (including any requiring hospi[INVESTIGATOR_059]).
Established nonserious infections (eg, acute upper respi[INVESTIGATOR_1092], simple urinary
tract infection) need not be considered exclusionary at the discretion of the investigator.
9. Has evidence of current active infection, including TB, or a nodule suspi[INVESTIGATOR_485596], unless definitively resolved
surgically or by [CONTACT_393388].
10. Has a history of latent or active granulomatous infection, including histoplasmosis or
coccidioidomycosis, prior to screening. Refer to inclusion criteria for information regarding
eligibility with a history of latent TB.
11. Has ever had a nontuberculous mycobacterial infection or serious opportunistic infection (eg,
cytomegalovirus causing colitis, Pneumocystis jiroveci , aspergillosis).
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
36
Ap
proved, Date: 14 December 202012. Is seropositive for antibodies to hepatitis C (HCV) without a history of clearance or successful
treatment, defined as being negative for HCV RNA in the past year and, if treated, at least [ADDRESS_623907] is not eligible for this
study.
13. Tests positive for HBV surface antigen (HBsAg), regardless of the results of other hepatitis B
tests. Subjects who test positive only for core antibody (anti-HBc) must undergo further
testing for hepatitis B DNA  (HBV DNA test). If the HBV DNA test is positive, the subject is
not eligible for this study. If the HBV DNA test is negative, the subject is eligibl e for this
study. In the event the HBV DNA test cannot be performed, the subject is not eligible for this
study.
14. Is infected with human immunodeficiency virus (HIV; positive serology for HIV antibody).
15. Has a concomitant diagnosis or any history of congestive heart failure or demyelinating
disease.
16. Has current signs or symptoms, or a history of severe, progressive, or uncontrolled renal,
hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic, systemic lupus
erythematosus, or psychiatric diseases.
17. Has a transplanted organ (except for corneal transplant performed > 3 months prior to
screening).
18. Has a history of lymphoproliferative disease including lymphoma, or signs and symptoms
suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size
or location (eg, nodes in the posterior triangle of the neck, supraclavicular, epi[INVESTIGATOR_60775], or
paraaortic areas), or splenomegaly.
19. Has any known malignancy or has a history of malignancy (except for basal cell carcinoma;
squamous cell carcinoma in situof the skin; or cervical carcinoma in situthat has been treated
with no evidence of recurrence; or squamous cell carcinoma of the skin that has been treated
with no evidence of recurrence within 5 years prior to screening).
20. Has previously undergone allergy immunotherapy for prevention of anaphylactic reactions.
21. Is unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack
of easy access to veins.
22. Has known allergies, hypersensitivity, or intolerance to ustekinumab or adalimumab or their
excipi[INVESTIGATOR_840] (refer to the ustekinumab Investigator Brochure [IB] and the adalimumab local
Prescribing Information).
23. Has a clinically significant substance abuse problem (eg, drugs or alcohol) at screening or
during the previous [ADDRESS_623908] 56 weeks in this study .
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
37
Ap
proved, Date: [ADDRESS_623909] (eg, may compromise the well-being) of the subject or that could prevent,
limit, or confound the protocol-specified assessments.
NOTE: Investigators should ensure that all study enrollment criteria have been met during
screening, and in particular, prior to initiating randomization. If a subject’s clinical status changes
(including any available laboratory results or receipt of additional medical records) during
screening such that he or she no longer meets all eligibility criteria, then the subject should be
excluded from participation in the study, before initiating randomization (and first study agent
administration). Section 17.4, Source Documentation, describes the required documentation to
support meeting the enrollment criteria.
[ADDRESS_623910] be willing and able to adhere to the following prohibitions and restrictions
during the study to be eligible for participation:
1. Must agree to conform to requirements regarding concomitant, prohibited, and
restricted therapy during the study as described in Section 8.
2. Must agree to continue to follow all applicable requirements that must be met for
enrollment in the study as described in Section 4.1and Section 4.2(eg, contraceptive
requirements).
3. Must not receive ustekinumab or adalimumab outside of the protocol. If a subject
intends to receive, or receives, ustekinumab or adalimumab or intends to participate, or
enrolls, in any other clinical study with an investigational agent, he/she should be
discontinued from study agent and also terminate study participation, with procedures
to be performed for the Early Termination Visit as shown in the Time and Events
Schedule PRIOR to receiving one of these agents.
4. Must agree not to receive a live virus or live bacterial vaccination, including a BCG
vaccination, during the study or for [ADDRESS_623911] continue the appropriate course
of therapy to completion.
5. TREATMENT ALLOCATION AND BLINDING
5.1. Treatment Allocation
Allocation to treatment group will be performed using a central randomization center by [CONTACT_485623] (IWRS). Subjects will be randomly assigned to 1 of 2
treatment groups based on a computer-generated randomization schedule prepared under the
supervision of the sponsor. Permuted block randomization with stratification variables including
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
38
Ap
proved, Date: 14 December 2020the use of steroids at baseline (Yes, No), CDAI score at baseline (≤ 300 or > 300), and ulcerations
>5 mm (Yes, No) will be used.
5.2. Blinding
At Week 0, subjects assigned to ustekinumab will receive an IV infusion of ustekinumab and 4 SC
injections of placebo to blind for adalimumab; subjects assigned to adalimumab will receive an IV
infusion of placebo to blind for ustekinumab and 4 SC injections of adalimumab (each 40 mg). At
Week 2, subjects will receive 2 SC injections of placebo (if in the ustekinumab group to blind for
ustekinumab) or adalimumab (each 40 mg). Beginning at Week 4 and continuing through Week
56, it is recommended that subjects self-administer SC injections of study agent or placebo,
generallyat home, q2w. If subjects need to give any injections at the site, eg, additional support or
training from unblinded site personnel is necessary, this will be done in a designated area, without
involvement of (and out of sight of) blinded personnel.
While the [ADDRESS_623912]’s source documents or diary. The label
will not identify the study agent in the container. The medication number will be entered in the
eCRF when the drug is dispensed. 
The ustekinumab and adalimumab placebo syringes will be identical in appearance and packaging;
however, the adalimumab and ustekinumab syringes will not be identical. For that reason, the
investigator site personnel will not be allowed to see the syringes out of the study agent containers
and subjects will be instructed to not discuss the syringes with them. To maintain the blind, at
Weeks [ADDRESS_623913]’s source documents or diary; after Week 2, this will be monitored by [CONTACT_485624].
The sponsor and site monitors will remain blinded to treatment assignments until after the Week [ADDRESS_623914], study blind can be broken by [CONTACT_485625], if deemed necessary by [CONTACT_093] (eg, if knowledge of a subject’s assigned treatment
is needed to ensure his or her welfare by [CONTACT_485626] 56).
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
39
Ap
proved, Date: [ADDRESS_623915] has had his or her
Week 56 medication dose. The investigator may, in an emergency, determine the identity of the
intervention if specific emergency treatment/course of action would be dictated by [CONTACT_485627], by [CONTACT_485628]. While the
responsibility to break the intervention code in emergency situations resides solely with the
investigator, it is recommended that the investigator contact [CONTACT_3552], if possible,
to discuss the particular situation before breaking the blind. Telephone contact [CONTACT_485629] [ADDRESS_623916]'s source documents in a secure manner.
Additionally, a given subject’s treatment assignment may be unblinded to the sponsor,
Independent Ethics Committee/Institutional Review Board, and site personnel to fulfill regulatory
reporting requirements for serious unexpected associated (SUA) adverse reactions.
A separate code break procedure will be available for use by [CONTACT_48873]’s Global Medical Safety
(GMS) group to allow for unblinding of individual subjects to comply with specific requests from
regulatory or health authorities.
Subjects who have had their treatment assignment unblinded by [CONTACT_485630] 20 to 24 weeks, at which time an early termination visit
should be performed.  This early termination visit ([ADDRESS_623917] study agent) is
considered mandatory, while attending scheduled study visits up to this time is optional.
6. DOS AGE AND ADMINISTRATION
Subjects randomized to ustekinumab will receive ~6m/kg IV induction at Week [ADDRESS_623918] SC administration occurring
at Week 8. Subjects randomized to adalimumab will receive 4 x 40 mg SC injections at Week 0
(160 mg total), followed by 2 SC injections (80 mg total) at Week [ADDRESS_623919] been completed, subjects will receive the
following:
 Group 1 (ustekinumab): An IV infusion of ustekinumab (approximating 6 mg/kg) and
4 SC injections of placebo for adalimumab
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
40
Ap
proved, Date: 14 December 2020The IV infusion of ustekinumab is weight-based, administered consistent with labelling, as
shown below:
- 260 mg (weight ≤ 55 kg)
- 390 mg (weight > 55 kg and ≤ 85 kg)
- 520 mg (weight > 85 kg)
 Group 2 (adalimumab): An IV infusion of placebo for ustekinumab and
4 SC injections of adalimumab (each 40 mg)
IV infusions (at Week 0) are to be administered over a period of at least [ADDRESS_623920], prior to the Week 0 IV study agent, for operational efficiency (eg, that way SC
injections can be administered after randomization while the IV infusion is prepared). In any case,
regardless of whichever treatment is administered first, it is mandatory that at least [ADDRESS_623921] been completed, subjects will receive the
following:
 Group 1 (ustekinumab): 2 SC injections of placebo
 Group 2 (adalimumab): 2 SC injections of adalimumab (each 40 mg)
Note: Because it is presumed that subjects will require initial assistance and training as they may
be inexperienced and unfamiliar with how to self-administer SC injections, all SC study agent
administrations at Weeks 0 and 2 will be performed (or supervised) by [CONTACT_485631] (with no other study personnel involved in handling of SC study agent outside of the
carton). At these visits, subjects will be trained to self-administer SC study agent by [CONTACT_485632]. The blinded and double
dummy Week 0 IV infusion can be administered by [CONTACT_127191].
Beginning at Week 4 (non-visit week) and continuing through Week 56, subjects will self-
administer study agent generally at home and will receive:
 Group 1 (ustekinumab): 1 SC injection q2w (ustekinumab 90 mg will be administered
every eighth week after Week 0, with placebo for adalimumab
administered at all other designated dosing weeks)
 Group 2 (adalimumab): 1 SC injection of adalimumab 40 mg q2w.
When study agent administration and a study visit occur on the same day, it is generally
recommended that subjects administer study agent at home, af terhis/her study visit, or if they need
to give it at the site, it must be in a designated area out of sight of blinded study personnel.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
41
Ap
proved, Date: [ADDRESS_623922] with a clinically important, active infection.
Investigators are required to evaluate subjects for any signs or symptoms of infection at scheduled
visits (see Time and Events Schedule ). If a subject develops a serious infection, including but not
limited to sepsis or pneumonia, discontinuation of study treatment must be considered.
7. TREATMENT COMPLIANCE
Study drug administration at Weeks [ADDRESS_623923]’s source documents or
diary with the assistance of an unblinded study site staff member who will be administering or
supervising study agent administration at these weeks. Thereafter, subjects will remove the
adhesive label from the exterior of the medication kit and place it in the diary, corresponding to
the date of administration. Study site personnel will utilize subject diaries at each visit to ensure
compliance and record at-home study agent administrations in the eCRF.
Additional details will be provided in a pharmacy manual/study site investigational product
manual that is provided separately.
8. CONCOMITANT THERAPY
8.1. Concomitant Therapi[INVESTIGATOR_485597].
All concomitant prescription therapi[INVESTIGATOR_014] (including vaccines) must be recorded in the eCRF.
Recorded information will include the name [CONTACT_11889], dose, start and stop dates, and its
reason for use.
8.1.1. Crohn’s Disease-specific Concomitant Medications
Initiation of standard immunomodulators (MTX, AZA, and 6-MP) or IV/oral corticosteroids (or
increases in dose) should be avoided as this will impact the efficacy analyses in this study. If
initiated, these treatments should be discontinued or tapered off as soon as medically tolerable and
appropriate; however, subjects can (and should) continue to receive study agent and attend all
study visits despi[INVESTIGATOR_485598] (or increasing dose) of any of these CD related medications, except
for those described as prohibited medications below (see Section 8.2).
[IP_ADDRESS]. Oral Corticosteroids
In order to allow study agent time to provide efficacy, it is recommended that corticosteroid doses
be maintained at a stable dose until approximately Week 8, unless a subject has significant disease
improvement or experiences corticosteroid side effects. Subjects receiving corticosteroids at Week
0 who are in clinical response at Week 8 mayinitiate corticosteroid tapering at Week 8 if medically
appropriate and tapering should be considered mandatory per the protocol starting at Week 16,
unless medically inappropriate. This tapering should follow the below-recommended schedule
(Table 1 ), without exceeding the prescribed magnitude or rate of tapering unless due to medical
necessity (eg, subject experiencing corticosteroid-related side effects).
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
42
Ap
proved, Date: 14 December 2020If a subjectexperiences worsening in his/her disease activity while tapering corticosteroids, further
dose decreases may be suspended, and the oral corticosteroid dose may be temporarily increased
if deemed necessary by [CONTACT_093], to attempt to return to response. For subjects whose
corticosteroid taper is interrupted on this basis, investigators should resume tapering as soon as
possible thereafter.
Table 1: Recommended Tapering Schedule for Oral Corticosteroids
Re
commended Tapering  Schedule f or Oral Corticosteroids (Other than Budesonide)
Dos
e > 15 mg/day prednisone or 
equivalent Taper daily dose by 5 mg/week until receiving 10 mg/day, then
continue tapering at 2.5 mg/week until 0 mg/day
Dos
e 11 to 15 mg/day prednisone or 
equivalent Taper daily dose to 10 mg/day for 1 week, then continue at
2.5 mg/week until 0 mg/day
Dos
e ≤ 10 mg/day prednisone or 
equivalent:Taper daily dose by 2.5 mg/week until 0 mg/day
Re
commended Tapering  Schedule f or Oral Budesonide
Sub
jects receiving budesonide should have their daily dose tapered by 3 mg every 3 weeks until 0 mg/day.
If
 medically necessary (due to worsening disease or symptoms), subjects may initiate oral
corticosteroids if needed to manage their disease, but these should be discontinued and/or tapered
off, as described above, as soon as clinically possible.
8.2. Prohibited Medications
In contrast to the concomitant medications described above, initiation of any of the following
medications is prohibited (until the last study agent administration at Week 56) and if initiated,
should result in discontinuation from further study agent, although such subjects should not
terminate study participation (unless enrolling in an interventional CD study or initiating a
commercial anti-TNF or anti-IL-12 or 23 biologic- as described further below), and are encouraged
to complete all visits through the next 20-24 weeks, at which point the mandatory early termination
visit should be performed.
 Immunomodulator agents other than AZA, 6-MP, or MTX (including but not limited to
6-TG, cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, tofacitinib and other JAK
inhibitors)
Note: AZA, 6-MP, and MTX (and corticosteroids) are NOT prohibited medications, so their
initiation does NOT necessitate discontinuation of study agent (as described above).
 Immunosuppressant biologic agents (including but not limited to commercial ustekinumab
or adalimumab, other TNF-antagonists, natalizumab, vedolizumab, and abatacept)
 Experimental or investigational CD medications
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
43
Ap
proved, Date: 14 December 2020Note: Until study treatment is completed (ie, after Week 56), subjects must not receive
ustekinumab or anti-TNF biologics outside of the protocol or participate in any other CD clinical
study with an investigational agent. If any of these occur prior to Week 56, subjects must not only
discontinue any further study agent, but also must terminate study participation, with performance
of the “early termination visit”. If the decision or realization that this is about to occur coincides
with a scheduledvisit, then the early termination visit (and assessments per the Schedule of Events)
should be performed in place of the scheduled visit, including the scheduling and performance of
the follow-up ileocolonoscopy (as soon as possible). The rationale for handling these
circumstances differently (ie, requiring study termination in addition to study agent
discontinuation) is that these interventions could result in confounded or uninterpretable
subsequent efficacy and safety data.
As protection of human research subjects is paramount, it is recognized that initiating these
prohibited therapi[INVESTIGATOR_485599].  However, initiation of the
above prohibited medications prior to Week 56 should be documented as a deviation from the
study protocol (unless study agent has already been discontinued or completed), and subjects must
be discontinued from receiving further study agent once these agents are started.
9. STUDY EVALUATIONS
9.1. Overview
The following subsections provide details on the evaluations to be conducted during the study. For
the timing of these events, refer to the Time and Events Schedule .
Week [ADDRESS_623924] clinic visits and assessments performed as indicated in the Time and Events
Schedule . Note that the Week 76 follow-up visit is recommended to be performed remotely, by
[CONTACT_756].
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
44
Ap
proved, Date: 14 December 2020Study visits should occur at the week indicated ±  8 days (except Week 2, which should occur ±4
days). Note that while out of window visits should be recorded as protocol deviations, it is
preferable to perform visits and procedures out of window than not perform them at all. One
exception may be if sufficient time has passed that it is now in-window for the next, subsequent
visit, in which case it is advised to contact [CONTACT_485633].
Study agent administration should not occur when a subject is experiencing a clinically important,
active infection, an example of an appropriate reason to deviate from protocol-specified windows
(which should then be documented appropriately).
The subject will be instructed to complete the CDAI diary card daily through Week 56.  For all
visits where a score needs to be calculated in real-time, the hematocrit value obtained at the
previous visit will be used when calculating the CDAI score.
9.2. Efficacy
9.2.1. CDAI
The CDAI will be assessed by [CONTACT_485634] 8 different CD-related variables (see
Attachments 4 and 5): extra-intestinal manifestations, abdominal mass, weight, hematocrit, total
numberof liquid stools, abdominal pain/crampi[INVESTIGATOR_007], use of antidiarrheal drug(s) and/or opi[INVESTIGATOR_858], and
general well-being.4,[ADDRESS_623925] recent hematocrit value (central laboratory) before the current visit
will be used for the calculation of CDAI. The CDAI should be completed before subjects begin
their preparation for any video ileocolonoscopy to prevent the ileocolonoscopy preparation from
interfering with CDAI results.  In the event that any of the 7 days that would normally be used for
CDAI calculations are impacted by [CONTACT_485635], or recovery from, an ileocolonoscopy,
these days should be skipped in recording the CDAI for that visit (instead using the closest 7 days
that were not impacted).
9.2.2. Video Ileocolonoscopy
During the screening period, prior to randomization, all subjects will have an ileocolonoscopy
performed, including attempts at intubation of the terminal ileum, which will be video-recorded
for subsequent central reading and scoring. A video ileocolonoscopy recorded within the [ADDRESS_623926] one segment and also
note whether or not any of the ulcers present exceed 0.5 cm in diameter. .At Week 52, within a
window ranging from 50 to 54 weeks, all subjects remaining in the study will undergo a second
ileocolonoscopy. Subjects who do not remain in the study at Week 52 (due to discontinuation of
study agent and/or termination of study participation) will instead have their follow-up
ileocolonoscopy at the early termination visit. All of these procedures will be video-recorded,
following the more detailed directions provided in the separate study reference (or
ileocolonoscopy) manual.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
45
Ap
proved, Date: 14 December 2020For efficacy endpoints (and to confirm study eligibility) screening and follow-up ileocolonoscopy
recordings at Week 52 (or early termination) will be assessed by a central reader blinded to
treatment regimens, using the SES-CD scoring system.
SES-CDScoring  System
The SES-CD scoring system, which ranges from 0 to 60, includes 4 variables, each considered in
5 segments of the bowel (the ileum, ascending colon, transverse colon, descending colon, and
rectum):
 Ulcer size:  0.1–0.5 cm; 0.5–2 cm; > 2 cm,
 Extent of ulcerated surface: < 10%; 10%–30%; > 30%,
 Extent of affected surface: < 50%; 50%–75%; > 75%, and
 Stenosis: Single or multiple and partially or totally occluded.
9.2.3. Crohn’s Disease-related Healthcare Utilization
Crohn’s disease-related healthcare utilization, including, but not limited to CD-related
hospi[INVESTIGATOR_602], surgery, and/or emergency room visitswill be collectedand entered into the eCRF
by [CONTACT_485636].
9.2.4 . C-reactive Protein and Fecal Calprotectin
C-reactive protein and fecal calprotectin will be evaluated during the study to monitor efficacy.
Stool samples for fecal calprotectin should not be collected on days impacted by [CONTACT_485637].
9.2.5. PROs
During the study, all PRO assessments should be conducted/completed before any tests,
procedures, or other consultations to prevent influencing subject perceptions.
[IP_ADDRESS]. IBDQ
The IBDQ is a validated disease-specific instrument composed of 32 Likert-scaled items (see
Attachment 1 ).16The total score ranges from 32 to 224 using the 7-point response options, with
higher scores indicating better health-related quality of life. A total IBDQ score > 170 is associated
with clinical remission. A change of 16 or more points in the total score is considered clinically
meaningful. The IBDQ scale contains 4 component subscales: bowel symptoms, systemic
symptoms, emotional function, and social function. Each subscale can be computed with total
scores ranging from 10 to 70, 5 to 35, 12 to 84, and 5 to 35, respectively.
[IP_ADDRESS]. PROMIS-29
The PROMIS-29 Questionnaire will be utilized for this study (see Attachment 2 ). PROMIS-[ADDRESS_623927]-reported health status.5 The
PROMIS-29 questionnaire measures physical function, anxiety, depression, fatigue, sleep
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
46
Ap
proved, Date: 14 December 2020disturbance, ability to participate in social roles and activities, and pain interference. The PROMIS-
29 also measures pain intensity on a 10-point scale from no pain (0) to worst pain imaginable
(10).13
[IP_ADDRESS]. WPAI-CD
The WPAI-CD is a validated 6-question instrument that measures the effect of CD symptoms on
a subject’s ability to work and perform normal daily activities (see Attachment 3 ). The recall period
for the WPAI-CD is up to the previous [ADDRESS_623928] confidentiality will be
maintained.
Samples for serum concentrations and antibodies to study agent will be collected at the visits
indicated in the Time and Events Schedule for subjects in both groups.  Serum concentrations and
antibodies to study agent will be assessed at the following timepoints:
 Serum concentrations:
 Ustekinumab Weeks 0, 8, 16, 32, 48, 52, and early termination if
applicable
 Adalimumab Weeks 0, 16, 52, and early termination if applicable
 Antibodies to study agent:
 Ustekinumab Weeks 0, 8, 16, 52, and early termination if
applicable
 Adalimumab Weeks 0, 16, 52, and early termination if applicable
Serum concentrations will be determined using a validated, sensitive, specific, and drug-tolerant
method by [CONTACT_43754]. Anti-drug assays will be performed for
ustekinumab and adalimumab using different, but drug-tolerant, validated assays by [CONTACT_485638]. Any comparison of the data will be descriptive, only. 
9.[ADDRESS_623929] be recorded on the Adverse Event
section of the eCRF.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
47
Ap
proved, Date: 14 December 2020Any clinically significant abnormalities persisting at the end of the study/early withdrawal will be
followed by [CONTACT_43727] a clinically stable endpoint is reached.
9.4 .1. Adverse Events
Adverse events (AEs) will be reported by [CONTACT_423] (or, when appropriate, by a caregiver) for the
duration of the study. Adverse events will be followed by [CONTACT_70443] 12, Adverse Event Reporting.
9.4 .2. Adverse Events Temporally Related to Infusion
Any AE (except laboratory abnormalities) that occurs during or within 1 hour after the IV infusion
of study intervention will be carefully evaluated.  Minor infusion-related AEs may be managed by
[CONTACT_247915]/or treating with antihistamines and/or acetaminophen
(paracetamol) as clinically indicated. If an IV infusion of study intervention is stopped because of
an AE that, in the opi[INVESTIGATOR_871], is not severe or does not result in a serious adverse
event (SAE), the infusion may be restarted with caution.
9.[ADDRESS_623930] any clinically relevant changes
occurring during the study in the AE section of the eCRF. The following tests will be performed
by [CONTACT_485639] , unless otherwise specified or
approved by [CONTACT_7195].
 Hematology assessments will include but are not limited to the following: hemoglobin,
hematocrit, platelet count, total and differential WBC count.
 Blood chemistry assessments will include but are not limited to the following: chemistry panel
(total and direct bilirubin, ALT, AST, alkaline phosphatase, albumin, total protein, calcium,
phosphate, sodium, potassium, chloride, blood urea nitrogen (BUN)/urea, and creatinine).
 Stool fecal calprotectin
 Serum and urine pregnancy testing for women of childbearing potential only
 Serology for HIV antibody, HBsAg, anti-HBs, anti-HBc, and hepatitis C virus antibody
Additional laboratory or pregnancy tests may be performed, as determined necessary by [CONTACT_160218].
For some tests related to screening criteria, existing local or central laboratory results are
acceptable to satisfy study requirements (eg, QuantiFERON-TB test, stool pathogens) provided
they were performed in the required time windows. Additionally, certain tests that are performed
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
48
Ap
proved, Date: 14 December 2020for study purposes may be performed locally with proper documentation (eg, inclusion on Form
1572). Appropriateness may be discussed with the medical monitor.
A medical monitor or delegate and the clinical site will be notified if prespecified abnormal
laboratory values defined in the Laboratory Manual are identified in any subject during the conduct
of the study.  In some cases it may be medically appropriate to repeat screening laboratory tests if
test values are outside of the required ranges; contact [CONTACT_1034]’s medical monitor to discuss
specific cases.
9.[ADDRESS_623931] be recorded in the eCRF or laboratory
requisition form. Refer to the Time and Events Schedule for the timing and frequency of all sample
collections and refer to the laboratory manual for the collection, handling, storage, and shipment
of samples.
9.5. Biomarkers
Biomarker assessments will be made to examine the biologic response to treatment and to identify
biomarkers that are relevant to adalimumab or ustekinumab treatment and/or CD. Assessments
(detailed below) will include the evaluation of relevant biomarkers in serum, blood, and/or stool
samples collected as specified in the Time and Events Schedule . Data collected from these samples
will be used for exploratory research that will include the following objectives:
1. To understand the molecular effects of adalimumab and ustekinumab.
2. To understand CD pathogenesis.
3. To understand why an individual may respond differently to adalimumab or ustekinumab.
4.    To develop new laboratory tests that could be used clinically in CD or other conditions.
9.5.1. Serum-based Biomarkers
Blood samples for serum-based biomarker analyses will be collected from all participants. Assays
to be performed may include proteins associated with proinflammatory and anti-inflammatory
effects, the recruitment and proliferation of cells associated with inflammation and repair, and
markers associated with tissue injury or repair. These analyses will include but not be limited to
IL-17A and IL-22.
9.5.2. Whole Blood-based Biomarkers
Whole blood samples will be collected from all participants to assess the effect of study
intervention on RNA expression profiles. Whole blood analyses may also examine RNA
expression associated with the pathogenesis of CD.
9.5.3. Physical Examinations, Vital Signs, Weight
Physical examinations, directed physical examinations (ie, examination for abdominal mass,
perianal fistula, and other fistulas), vital signs, and weight are to be performed/measured at the
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
49
Ap
proved, Date: 14 December 2020times shown in the Times and Events Schedule . Vital signs are to include temperature, pulse/heart
rate, respi[INVESTIGATOR_697], and blood pressure.
At Week 0, vital signs will be obtained before, approximately every 30 minutes during, and twice
(at approximately 30-minute intervals) after completion of the IV infusion, and before as well as
approximately [ADDRESS_623932] COMPLETION/DISCONTINUATION OF STUDY TREATMENT/
WITHDRAWAL FROM THE STUDY
10.1. Completion
A subject will be considered to have completed the study if he or she has completed the final visit
at Week 76. 
Subjects will be considered to have completed the primary (blinded) efficacy portion of the study
if they have completed the Week 52 visit assessments (or an early termination visit within 35 days
of the Week 52 visit target date).
10.2. Discontinuation of Treatment
A subject's study treatment should be discontinued if:
 The investigator or the medical monitor believes that for safety reasons (eg, an AE) it is in the
best interest of the subject to stop treatment.
 The subject required emergency unblinding of their study treatment.
 The subjectbecomes pregnant or plans a pregnancy within the study period or within [ADDRESS_623933] study agent administration.
 The subject is deemed ineligible to receive further study treatment according to the following
TB screening criteria: 
 A diagnosis of active TB is made.
 A subject has symptoms suggestive of active TB based on follow-up assessment
questions and/or physical examination, or has had recent close contact [CONTACT_4490] a person with
active TB, and cannot or will not continue to undergo additional evaluation. 
 A subject undergoing continued evaluation has a chest radiograph with evidence of
current active TB and/or a positive QuantiFERON-TB test result and/or a positive
tuberculin skin test result in countries in which the QuantiFERON-TB is not
approved/registered unless active TB can be ruled out and appropriate treatment for latent
TB can be initiated either prior to or simultaneously with the next administration of study
agent and continued to completion. (Note: Consideration for study agent discontinuation
may be given for subjects diagnosed with latent TB in countries with high multidrug-
resistant TB burden [eg, South Africa, Bulgaria, and the Russian Federation]).
 A subject receiving treatment for latent TB discontinues this treatment prematurely or is
noncompliant with the therapy.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
50
Ap
proved, Date: 14 December 2020 The subject experiences serious adverse reactions related to either an injection or infusion, he
or she should be discontinued from further study injections. Discontinuation of study agent
administration must be considered for subjects who develop non-serious, but severe injection
site or infusion reaction (as described in Section 12.1.3).
 The subject develops a malignancy including squamous cell skin cancer. Consideration may
be given to allow subjects to continue to receive study agent if they develop ≤ 2 basal cell skin
cancers that are adequately treated with no evidence of residual disease.
 The initiation of the following protocol-prohibited medications at any time during the study:
 Immune suppressing immunomodulatory agents other than 6-MP, AZA or MTX
(including but not limited to 6-TG, cyclosporine, tacrolimus, sirolimus, mycophenolate
mofetil, tofacitinib and other JAK inhibitors)
 Immunosuppressant biologic agents (including but not limited to commercial
ustekinumab or adalimumab, other TNF-antagonists, natalizumab, vedolizumab, and
abatacept)
 Experimental or investigational CD medications
 A serious opportunistic infection occurs.
 The subject  withdraws consent for further administration of study agent.
 Subjects who have not experienced any improvement in their symptoms and/or CD disease
activity by [CONTACT_10585] 24 should be considered for discontinuation on the basis of lack of efficacy.
 The subject has CD-related surgeries that will preclude the future ability to assess efficacy
through the CDAI. Surgeries that are thought to represent a lack of efficacy of study agent
should be considered for discontinuation at the discretion of the Investigator other than minor
procedures (eg, placement of a seton or cutaneous drainage of an abscess).
Subjects who discontinue study agent (for the reasons above) before the end of planned study agent
treatment (Week 56), should not terminate their study participation (unless enrolling in an
interventional CD study or initiating a commercial anti-TNF or anti-IL-12 or 23 biologic, as
described further below).  Instead, subjects discontinuing study agent are encouraged to complete
study visits through the next 20-24 weeks, at which an early termination visit should be performed. 
This early termination visit (20-[ADDRESS_623934] study agent) is considered mandatory, while
attending scheduled study visits up to this time is optional.
If subjects refuse to remain in the study to perform this early termination visit at least [ADDRESS_623935]’s desire to withdraw their consent for further study
participation should be accommodated by [CONTACT_485640]/possible. Thus, if possible, the early termination visit should be moved up and
performed prior to when the subject might withdraw their consent.
Note: The Week 76 visit, which can occur by [CONTACT_648], applies to all subjects, even those who
discontinued study agent prior to Week 56 or who otherwise terminated study participation (eg,
withdrawal of consent) unless they specifically do not consent to this telephone follow-up from
the site.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
51
Ap
proved, Date: [ADDRESS_623936] will be withdrawn from the study for any of the following reasons:
 Lost to follow-up
 Withdrawal of consent for study participation (distinct from withdrawal of consent to receive
study agent)
 Death
 Sponsor decision (eg, initiating a commercial anti-TNF, anti-IL-12 or anti-IL-23 biologic such
as ustekinumab or adalimumab outside of the protocol or plans to receive an investigational
agent in an interventional CD study).
Subjects who terminate study participation will not be required to return to the site for any follow-
up assessments; however, these subjects should complete the safety and efficacy evaluations
specified for Early Termination in the Time and Events Schedule at the time they terminate study
participation (including ileocolonoscopy), even if this coincides with a scheduled visit (provided
they are willing/consent to do so). Also, of note, the Week 76 visit (which can occur by [CONTACT_648])
applies to all subjects, even those who discontinued study agent prior to Week 56 or who otherwise
terminated study participation (eg, withdrawal of consent) unless they specifically do not consent
to this telephone follow up from the site.
If a subject is lost to follow-up, every reasonable effort must be made by [CONTACT_485641]/withdrawal. The measures
taken to follow up must be documented.
When a subject withdraws before completing the study, the reason for withdrawal is to be
documented in the eCRF and in the source document. Study agent assigned to the withdrawn
subject may not be assigned to another subject.  Subjects who withdraw will not be replaced.
11. STATISTICAL METHODS
Statistical analysis will be done by [CONTACT_35522]. A general
description of the statistical methods to be used to analyze the efficacy and safety data is outlined
below. Specific details will be provided in the Statistical Analysis Plan.
11.1. Subject Information
The disposition information of all randomized subjects, including the number of subjects who
discontinued study agent and terminated study participation, will be summarized by [CONTACT_485642]. The reasons for study agent discontinuation and studyparticipation termination will be also
summarized by [CONTACT_1570]. Demographic data and disease characteristics at baseline will be
summarized by [CONTACT_1570].
11.2. Sample Size Determination
As stated above, the primary objective of this study is to explore the hypothesis that one year of
treatment with ustekinumab is superior to one year of treatment with adalimumab, as assessed by
[CONTACT_485643]® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
52
Ap
proved, Date: 14 December 2020the primary endpoint of remission (CDAI<150) after one year of treatment (ie, at the Week 52
visit).
The assumptions that form the basis for sample size and power calculations in this protocol to
support the primary endpoint were based on available Phase 3 registrational studies. For
ustekinumab, induction data from the UNITI-2 study and maintenance results from IM-UNITI
were utilized, focusing on the anti-TNF-naïve subset of subjects.10 For adalimumab assumptions,
data from the open-label induction and then maintenance phase of the CHARM7 study were
utilized, again focusing on the anti-TNF naïve subset of subjects.
In the UNITI-2 trial, 58% of subjects who were anti-TNF naïve responded to induction with
~6 mg/kg IV ustekinumab.10 Among ustekinumab induction responders, 65% were in remission at
Week 44 on 90 mg SC q8w (ie, 38% of the original treated subjects [58% x 65%]). In order to
model a treat-through study design, the subjects who were initial non-responders to ustekinumab
induction were also incorporated into the estimates. Among the remaining 42% of initial anti-TNF
naïve UNITI-2 recipi[INVESTIGATOR_485600], 42% of these ustekinumab induction non-responders
were in remission at Week 44 (ie, 18% of the original treated subjects [42% x 42%]). Thus, the
overall estimate for remission after one year of treatment in the proposed study is 38% + 18%, or
56%of all treated subjects for the ustekinumab group.
In the Phase 3 adalimumab CHARM study, 59% of the anti-TNF naïve subjects responded to open-
label induction therapy with adalimumab;20 of these induction responders, 42% were in remission
with 40 mg of adalimumab every other week at the Week 56 primary endpoint (ie, 25% of the
original treated subjects [59% x 42%]).7 Among the remaining 41% of subjects who did not
respond to induction, it is not reported what percentage were in remission at 56 weeks, though
remission would typi[INVESTIGATOR_485601]-responders than in responders.
Nonetheless, a similar proportion (40%) of these induction non-responders are assumed to be in
remission at one year (representing remission at one year in another 16% of the original treated
subjects [41% x 40%]). The resulting overall remission rate after one year of adalimumab
treatment is 41%(25%+16%).
The Phase 3b SONIC study was also examined to evaluate adalimumab assumptions, since it was
a one year treat-through study of another anti-TNF (infliximab) in the relevant anti-TNF naïve
population. In SONIC, the remission rate in the infliximab monotherapy arm at Week 50 was 39.6,6
similar to the estimate of 41% calculated above for adalimumab.
Assuming a 41% clinical remission rate at Week 52 in the adalimumab group and 56% in the
ustekinumab group (a “delta” of 15%), 175 subjects per treatment group will yield power of
approximately 80% for superiority ( Table 2 ), at a significance level of 0.05 (2-sided, Mantel-
Haenszel test).
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
53
Ap
proved, Date: 14 December 2020Table 2: Power to detect a treatment effect based on different proportions of subjects achieving
clinical remission at Week 52 (n=175 each group)
Clinical remission at Week 52 (%)PowerAdalimumab Ustekinumab
  41% 54% 68%
56%
 80%
59%
 92%
38% 53%
 81%
54% 85%
55% 89%
[ADDRESS_623937] major secondary endpoint will
be tested only if the primary endpoint is positive, and the subsequent endpoint(s) will be tested
only if the preceding endpoint in the hierarchy is positive.
11.3.1. Primary Efficacy Endpoint
The proportion of subjects with clinical remission (defined as a CDAI score <150) at Week 52.
11.3.2. Major Secondary Efficacy Endpoints
The proportion of subjects with:
 Corticosteroid-free remission at Week 52 (defined as a CDAI score <[ADDRESS_623938] 30 days prior to Week 52)
 Clinical response (defined as a CDAI score decrease ≥100 from baseline) at Week 52
 PRO-2 symptom remission at Week 52 (defined as an abdominal pain [AP] mean daily score
at or below 1 and also stool frequency [SF] mean daily score at or below 3, ie, AP ≤1 and 
SF ≤3). PRO-2 are the stool frequency and abdominal pain scores reported as part of the
CDAI.
 Clinical remission (defined as CDAI <150) at Week 16
 Endoscopic remission (defined as an SES-CD score ≤3, or SES-CD =0 for subjects who enter
the study with an SES-CD =3) at Week 52
11.3.3. Secondary Endpoints
 The proportion of subjects with clinical remission (defined as CDAI < 150), compared at each
postbaseline visit through Week 52
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
54
Ap
proved, Date: 14 December 2020 The proportion of subjects with clinical response (defined as a CDAI score decrease ≥100
from baseline), compared at each postbaseline visit through Week 52
 The proportion of subjects with durable clinical response at Week 52 (defined as CDAI>100
decrease from baseline at Week 52 and at ≥80% of all visits between Week 16 and Week 52)
 The proportion of subjects with durable clinical remission at Week 52 (defined as CDAI <150
at Week 52 and at ≥80% of all visits between Week 16 and Week 52)
 Absence and/or resolution of AP, defined as a mean daily CDAI AP score of 0 in the week
prior to the visit among subjects with mean AP >0 at baseline, compared at each postbaseline
visit through Week 52
 Absence and/or resolution of diarrhea, defined as no loose or watery stools in the week prior
to the visit (ie, SF CDAI sub-score = 0) among subjects with mean SF >1 at baseline,
compared at each postbaseline visit through Week 52
 The proportion of subjects with clinical and biomarker remission, defined as the proportion of
subjects with CDAI<150, CRP <3 mg/L, and also fecal calprotectin ≤250 µg/g, compared at
We
eks 8, 16 and 52
 The proportion of subjects with at least one AE, and subcategories of AEs including
infections, SAEs, and serious infections
 The proportion of subjects with anti-drug antibodies
11.3.4 . Other Endpoints
Efficacy Endpoints at (or through) Week 52:
 The change in CDAI score from baseline at all postbaseline visits through Week 52
 Maintenance of clinical remission, defined as CDAI <150 at Week 52, among subjects in
remission at Week 16
 Maintenance of clinical response, defined as CDAI decreased at least 100 from baseline at
Week 52 among subjects in response [CDAI decrease at least 100 points from baseline] at
Week 16
 The time to first flare (a flare is defined as an increase in CDAI score of > 100 points at any
subsequent visits through Week 52 [based upon loss of clinical response]) among subjects in
clinical response at Week 16
 The change from baseline in the sum of the number of stools and the AP scores in the prior 7
days, compared individually and combined (sum PRO-2), without weighting, at all
postbaseline visits through Week 52
 The change in the weighted (as per the CDAI) sum of the AP and SF subscores of the CDAI
from baseline at all postbaseline visits through Week 52 (PRO-2 weighted)
 PRO-2 symptom improvement/response, defined as at least a 1 point improvement (or a mean
score of zero) in mean daily CDAI AP score from baseline, and also a reduction in SF mean
daily score of 3 or more (or a mean score of zero) from baseline, compared at each visit
through Week 52
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
55
Ap
proved, Date: 14 December 2020 PRO-2 symptom remission, defined as an AP mean daily score at or below 1 and a SF mean
daily score at or below 3, ie, AP ≤1 and SF ≤3), compared at each visit through Week 52
 AP improvement, defined as a 1 point or greater improvement in mean daily CDAI AP score
from baseline, or a mean score of zero, among subjects with mean AP >0 at baseline,
compared at each visit through Week 52
 Reduction in frequency of diarrhea, defined as a reduction of at least 3 (or a mean number <1)
in SF (ie, mean daily number of liquid or very soft stools from CDAI in the week prior to the
visit) from baseline, among subjects with mean SF >1 at baseline, compared at each visit
through Week 52
 The proportion of subjects with corticosteroid-free response at Week 52 (defined as a CDAI
score decrease ≥[ADDRESS_623939] 30 days prior
to Week 52)
 The proportion of subjects with corticosteroid-free remission at Week 52 (defined as a CDAI
score <[ADDRESS_623940] 30 days prior to Week 52) among
subjects who were on corticosteroids at baseline
 The proportion of subjects with corticosteroid-free response at Week 52 (defined as a CDAI
score decrease ≥[ADDRESS_623941] 30 days prior
to Week 52) among subjects who were on corticosteroids at baseline
 The total number of visits subjects are in steroid-free remission through Week 52
 The proportion of subjects with endoscopic response (defined as a reduction in SES-CD score
by 50% from baseline, or SES-CD score ≤3. For subjects with SES-CD=3 at baseline, SES-
CD=0) at Week 52
 The change from baseline in SES-CD at Week 52
 The proportion of subjects with endoscopic improvement (change in SES-CD score of at least
3 points) at Week 52
 The proportion of subjects with a minimum of 25% improvement from baseline in SES-CD
score at Week 52
 The proportion of subjects with fistula resolution (closure of all open/draining
perianal/perirectal fistulas) compared at each postbaseline visit through Week 52 among
subjects with one or more open/draining perianal or perirectal fistulas at baseline
 The proportion of subjects with fistula response (defined as closure of 50% of open/draining
perianal/perirectal fistulas) compared at each postbaseline visit through Week 52 among
subjects with one or more open/draining perianal or perirectal fistulas at baseline
 The change from baseline in CRP concentration at all postbaseline visits through Week 52
 The proportion of subjects with normalization of CRP (defined as ≤3 mg/L) compared at each
postbaseline visit through Week 52 among subjects with abnormal CRP (>3 mg/L) at baseline
 The change from baseline in fecal calprotectin concentration, compared at Weeks 8, 16, and
52
 The proportion of subjects with fecal calprotectin ≤250 µg/g, compared at Weeks 8, 16, and
52 among subjects with baseline fecal calprotectin at >250 µg/g at baseline
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
56
Ap
proved, Date: 14 December 2020 The proportion of subjects with fecal calprotectin ≤100 µg/g at Weeks 8, 16 and 52 among
subjects with fecal calprotectin >250 µg/g at baseline
 The proportion of subjects with clinical remission anda≥50% reduction from baseline in CRP
or fecal calprotectin compared at Weeks 8, 16, and 52
 The proportion of subjects with clinical remission and a ≥50% reduction from baseline in CRP
or fecal calprotectin, comparedat Weeks 8, 16, and52, among participants with elevated CRP
(>3 mg/L) or fecal calprotectin >250 µg/g at baseline
 The proportion of subjects with clinical and biomarker remission, defined as CDAI < 150,
CRP <3 mg/L, and also fecal calprotectin ≤250 µg/g, comparedat Weeks 8, 16, and52, among
pa
rticipants with elevated CRP (>3 mg/L) or fecal calprotectin >250 µg/g at baseline
 The proportion of subjects with clinical and biomarker response (clinical response and ≥50%
reduction from baseline in CRP or fecal calprotectin) compared at Weeks 8, 16, and 52
 The proportion of subjects with clinical and biomarker response (clinical response and ≥50%
reduction from baseline in CRP or fecal calprotectin) compared at Weeks8, 16, and 52, among
participants with elevated CRP (>3 mg/L) or fecal calprotectin (>250 µg/g) at baseline
 The proportion of subjects with clinical response, CRP <3 mg/L, and fecal calprotectin ≤250
µg
/g at Weeks 8, 16 and 52
 The proportion of subjects with clinical response, CRP <3 mg/L, and fecal calprotectin ≤250
µg
/g at Weeks 8, 16, and 52, among participants with elevated CRP (>3 mg/L) or fecal
calprotectin >250 µg/g at baseline
 The proportion ofsubjects who are on concomitant narcotic pain medications for CD
 The proportion of subjects able to eliminate concomitant narcotic pain medication use for CD
 The total number of days subjects are off narcotic pain medications for CD through Week 52
among subjects who are on narcotic pain medication for CD at baseline
PRO Endpoints:
 The change from baseline in the IBDQ score (including IBDQ domains), compared at Weeks
8, 16, and 52
 The proportion of subjects with IBDQ response (≥16-point improvement from baseline),
compared at Weeks 8, 16, and 52
 The proportion of subjects with IBDQ remission (IBDQ score >170), compared at Weeks 8,
16, and 52
 The change from baseline in the PROMIS-29domains ofAnxiety Score, Depression Score,
Fatigue Score, Pain Interference Score, Sleep Disturbance Score, Ability to Participate in
Social Roles and Activities Score, Physical Function Score, and Pain Intensity Score
compared at Weeks 8, 16, and 52 (results reported separately for each domain)
 The proportion of subjects with a T-score decrease of ≥5 in the domains of Anxiety Score,
Depression Score, Fatigue Score, Pain Interference Score, Sleep Disturbance Score at Weeks
8, 16, and 52 (results reported separately for each domain)
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
57
Ap
proved, Date: 14 December 2020 The proportion of subjects with a T-score increase of ≥5 in the domains of Ability to
Participate in Social Roles and Activities Score, and Physical Function Score at Weeks 8, 16,
and 52 (results reported separately for each domain)
 The proportion of subjects with a T-score decrease of ≥3 in the domains of Anxiety Score,
Depression Score, Fatigue Score, Pain Interference Score, Sleep Disturbance Score at Weeks
8, 16, and 52 (results reported separately for each domain)
 The proportion of subjects with a T-score increase of ≥3 in the domains of Ability to
Participate in Social Roles and Activities Score, and Physical Function Score at Weeks 8, 16,
and 52 (results reported separately for each domain)
 The proportion of subjects with a score decrease of ≥½ baseline standard deviation in Pain
Intensity Score at Weeks 8, 16, and 52
 The proportion of subjects with a T-score decrease of ≥5 in Anxiety Score, Depression Score,
Fatigue Score, Pain Interference Score, Sleep Disturbance Score and increase of ≥5 in ability
to participate in social roles and activities, and physical function score,  at Weeks 8, 16, and
52 
 The proportion of subjects with a T-score decrease of ≥3 in Anxiety Score, Depression Score,
Fatigue Score, Pain Interference Score, Sleep Disturbance Score and increase of ≥3 in ability
to participate in social roles and activities, and physical function score,  at Weeks 8, 16, and
52
 Change from baseline in combined pain score from PROMIS-29 and number of liquid or soft
stools from CDAI, compared at Weeks 8, 16, and 52
 The change from baseline in the WPAI questionnaire, compared at Weeks 8, 16, and 52
Healthcare resource utilization endpoints:
 The proportion of subjects with CD-related hospi[INVESTIGATOR_059], surgeries, or initiation of non-
study alternate biologic for CD through Week 52
 The proportion of subjects with CD-related hospi[INVESTIGATOR_485602] 52
 The proportion of subjects initiating a non-study alternate biologic for CD through Week 52
 The proportion of subjects with CD-related hospi[INVESTIGATOR_355241] 52
 The proportion of subjects with CD-related surgeries through Week 52
 The proportion of subjects with a CD-related ER visit through Week 52
 The total number of days a subject has a CD-related hospi[INVESTIGATOR_355241] 52
 The proportion of subjects with an endoscopic procedure related to CD (not protocol-directed)
through Week 52
Endpoints to be compared at Week 56 and/or 76:
 The proportion of subjects with CD-related hospi[INVESTIGATOR_059], surgeries, or initiation of biologic
therapy for CD outside of the protocol through Week 76
 The proportion of subjects with CD-related hospi[INVESTIGATOR_485602] 76
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
58
Ap
proved, Date: 14 December 2020 The proportion of subjects initiating a non-study alternate biologic for CD through Week 76
 The proportion of subjects with CD-related hospi[INVESTIGATOR_355241] 76
 The proportion of subjects with CD-related surgeries through Week 76
 The proportion of subjects with clinical response at Week 56
 The proportion of subjects with clinical remission at Week 56
 The change from baseline in CDAI at Week 56
 The proportion of subjects with at least one AE, and subcategories of AEs including
infections, SAEs, and serious infections through Week 76
 Normalization of CRP (defined as ≤3 mg/L) at Week 56 among subjects with abnormal CRP
(>3 mg/L) at baseline
 The total time in steroid-free remission through Week 56
 The time to first flare among subjects in clinical response at Week 16 (defined as an increase
in CDAI score of >100 points) through Week 56 (based upon loss of clinical response).
11.4 . Efficacy Analyses
Descriptive statistics (eg, mean, median, standard deviation, interquartile range, minimum, and
maximum) will be used to summarize continuous variables. Counts and percentages will be used
to summarize categorical variables. Graphical data displays (eg, line plots) may also be used to
summarize the data whenever appropriate. Listings may also be utilized to present data at a subject
level.
All endpoints will be based on a superiority comparison between the 2 randomized groups
(ustekinumab treatment and adalimumab treatment). All randomized subjects will be included in
the efficacy analyses. All efficacy analyses will be based on intent-to-treat principle.
For the primary endpoint, the proportion of subjects in clinical remission at Week [ADDRESS_623942], stratified by [CONTACT_485616] 0 (yes
or no), baseline CDAI score (≤ 300 or > 300), and any ulceration > 5 mm (Yes, No) at a
significance level of 0.05.
The endpoints listed Sections 11.3.2 - 11.3.4 will be compared between the ustekinumab treatment
group and the adalimumab treatment group.
Treatment failure rules will override the response status (eg, clinical response, clinical remission,
and mucosal healing). Subjects who meet any of the following criteria for treatment failure will be
considered to not have achieved their dichotomous efficacy endpoints from the time the treatment
failure occurs onwards:
 Had a CD-related surgery due to lack of efficacy
OR
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
59
Ap
proved, Date: 14 December 2020 Discontinued study agent due to an AE of worsening CD or due to lack of efficacy
OR
 Had a prohibited change in concomitant medications (to be detailed in the Statistical Analysis
Plan).
For continuous efficacy endpoints, the baseline value will be carried forward from the time the
treatment failure occurs onwards.
Subjects with missing data, defined as those who terminated the study prior to the designated visit
or subjects who have a missing value at the designated visit, will be considered to not have
achieved their dichotomous efficacy endpoints. For continuous endpoints, the last available value
will be carried forward for subjects with missing data.
Crohn’s disease-related healthcare utilization for each subject will be analyzed according to the
assigned treatment regardless of the actual treatment received.
11.5. Pharmacokinetic and Immunogenicity Analyses
Descriptive statistics of the serum study agent concentrations will be calculated at each sampling
time point.  Serum study agent concentrations over time will be summarized for each treatment
group.
Concentrations below the lowest quantifiable concentration will be treated as zero in the summary
statistics.
The incidence of antibodies to study agent (immunogenicity) will be summarized for all subjects
who receive any study agent and have appropriate samples for detection of antibodies to
ustekinumab.
11.6. Safety Analyses
Safety will be assessed by [CONTACT_485614] 76. All
subjects who receive at least 1 administration of study agent will be included in the safety analyses.
Subjects will be analyzed according to the actual treatment received.
11.6.1. Adverse Events
The verbatim terms used in the eCRF by [CONTACT_130420] (MedDRA). Treatment-emergent AEs are AEs with
onset during the treatment phase or that are a consequence of a pre-existing condition that has
worsened since baseline. All reported AEs will be included in the analysis. For each AE, the
percentage of subjects who experience at least [ADDRESS_623943] narratives may be provided, as appropriate, for those
subjects who die, who discontinue treatment due to an AE, or who experience a severe or a serious
AE.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
60
Ap
proved, Date: 14 December 2020Adverse events will be assessed by [CONTACT_485644]:
 Adverse events (AEs)
 Serious adverse events (SAEs)
 Reasonably related AEs (very likely, probable, possible as assessed by [CONTACT_093])
 Discontinuation of study agent due to AEs
 Infections and serious infections
 Injection site reactions
 Infusion-related AEs (during or within 1 hour of an ustekinumab infusion)
 Malignancies.
11.6.2. Clinical Laboratory Tests
The following will be used to assess the safety of subjects:
 Laboratory parameters (hematology and chemistry) and change from baseline in these
laboratory parameters
 The incidence of markedly abnormal laboratory parameters
Definitions for markedly abnormal results for each laboratory parameter will be defined in the
Statistical Analysis Plan.
11.7. Interim Analysis
No interim analysis is planned for this study.
12. ADVERSE EVENT REPORTING
Timely, accurate, and complete reporting and analysis of safety information from clinical studies
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by
[CONTACT_67819]. The sponsor has established Standard Operating Procedures in
conformity with regulatory requirements worldwide to ensure appropriate reporting of safety
information; all clinical studies conducted by [CONTACT_70442].
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Events
An AE is any untoward medical occurrence in a clinical study subject administered a medicinal
(investigational or non-investigational) product. An AE does not necessarily have a causal
relationship with the treatment. An AE can therefore be any unfavorable and unintended sign
(including an abnormal finding), symptom, or disease temporally associated with the use of a
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
61
Ap
proved, Date: 14 December 2020medicinal (investigational or non-investigational) product, whether or not related to that medicinal
(investigational or non-investigational) product. (Definition per International Conference on
Harmonisation [ICH]).
This includes any occurrence that is new in onset or aggravated in severity or frequency from the
baseline condition, or abnormal results of diagnostic procedures, including laboratory test
abnormalities.
Note: The sponsor collects AEs starting with the signing of the Informed Consent Form (ICF; refer
to Section 12.3.1, All Adverse Events, for time of last AE recording).
Serious Adverse Events (SAEs)
An SAE based on ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for
Human Use is any untoward medical occurrence that at any dose:
 Results in death
 Is life-threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that
hypothetically might have caused death if it were more severe.)
 Requires inpatient hospi[INVESTIGATOR_1081]
 Results in persistent or significant disability/incapacity
 Is a congenital anomaly/birth defect
 Is a suspected transmission of any infectious agent via a medicinal product
 Is Medically Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is
also appropriate in other situations, such as important medical events that may not be immediately
life threatening or result in death or hospi[INVESTIGATOR_70364], and whether these
should be considered serious.
If a serious and unexpected AE occurs for which there is evidence suggesting a causal relationship
between the study drug and the event (eg, death from anaphylaxis), the event must be reported as
a serious and unexpected suspected adverse reaction (S[LOCATION_003]R) even if it is a component of the
study endpoint (eg, all-cause mortality).
Unlisted (Unexpected) Adverse Events/Reference Safety Information
An AE is considered unlisted if the nature or severity is not consistent with the applicable product
reference safety information. The expectedness of an AE will be determined by [CONTACT_485645].
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
62
Ap
proved, Date: 14 December 2020Adverse Events Associated with the Use of the Drug
An AE is considered associated with the use of the drug if the attribution is possible, probable, or
very likely by [CONTACT_23826] 12.1.2, Attribution Definitions.
12.1.2. Attribution Definitions
Not Related: An AE that is not related to the use of the drug.
Doubtful: An AE for which an alternative explanation is more likely, eg, concomitant drug(s),
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely.
Possible: An AE that might be due to the use of the drug. An alternative explanation,
eg, concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is
reasonable; therefore, the causal relationship cannot be excluded.
Probable: An AE that might be due to the use of the drug. The relationship in time is suggestive
(eg, confirmed by [CONTACT_23827]). An alternative explanation is less likely, eg, concomitant drug(s),
concomitant disease(s).
Very Likely: An AE that is listed as a possible adverse reaction and cannot be reasonably
explained by [CONTACT_4867], eg, concomitant drug(s), concomitant disease(s). The
relationship in time is very suggestive (eg, it is confirmed by [CONTACT_35719]).
12.1.3. Severity Criteria
An assessment of severity grade will be made using the following general categorical descriptors:
Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not
interfering with everyday activities.
Moderate: Sufficient discomfort is present to cause interference with normal activity.
Severe: Extreme distress, causing significant impairment of functioning or incapacitation.
Prevents normal everyday activities.
The investigator should use clinical judgment in assessing the severity of events not directly
experienced by [CONTACT_423] (eg, laboratory abnormalities).
12.2. Special Reporting Situations
Safety events of interest on a sponsor study drug that may require expedited reporting or safety
evaluation include, but are not limited to:
 Overdose of a sponsor study drug
 Suspected abuse/misuse of a sponsor study drug
 Accidental or occupational exposure to a sponsor study drug
 Any failure of expected pharmacologic action (ie, lack of effect) of a sponsor study drug
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
63
Ap
proved, Date: 14 December 2020 Unexpected therapeutic or clinical benefit from use of a sponsor study drug
 Medication error involving a sponsor product (with or without subject exposure to the sponsor
study drug, eg, name [CONTACT_2976])
 Exposure to a sponsor study drug from breastfeeding
Special reporting situations should be recorded in the eCRF. Any special reporting situation that
meets the criteria of a serious AE should be recorded on the serious AE page of the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All AEs and special reporting situations, whether serious or non-serious, will be reported from the
time a signed and dated ICF is obtained until completion of the subject's last study-related
procedure, which may include contact [CONTACT_20687]-up of safety. Serious AEs, including those
spontaneously reported to the investigator within [ADDRESS_623944] be
recorded using medical terminology in the source document and the eCRF. Whenever possible,
diagnoses should be given when signs and symptoms are due to a common etiology (eg, cough,
runny nose, sneezing, sore throat, and head congestion should be reported as "upper respi[INVESTIGATOR_130229]"). Investigators must record in the eCRF their opi[INVESTIGATOR_160146]. All measures required for AE management must be recorded in the source
document and reported according to sponsor instructions.
The sponsor assumes responsibility for appropriate reporting of AEs to the regulatory authorities.
The sponsor will also report to the investigator (and the head of the investigational institute where
required) all SAEs that are unlisted (unexpected) and associated with the use of the drug with the
exception of events of CD and related common manifestations (eg, abdominal pain, diarrhea,
nausea, vomiting, fistula, and rectal bleeding).  The investigator (or sponsor where required) must
report these events to the appropriate Independent Ethics Committee/Institutional Review Board
(IEC/IRB) that approved the protocol unless otherwise required and documented by [CONTACT_6179]/IRB.
Serious AEs relating to lack of efficacy (eg, events attributed to CD or related symptoms such as
abdominal pain, diarrhea, nausea, vomiting, fistula, and rectal bleeding) or progression of the
disease under study (ie, stenosis, stricture, ileus, or bowel obstruction) will not be individually
unblinded for expedited reporting (with the exception of fistula complications or fistulas events
that are indicated by [CONTACT_485646]).
Cases will be collectively assessed with all events (including those assessed as unrelated by
[CONTACT_431]) at sponsor database locks from this and other ongoing sponsor studies. If such an
assessment were to conclude that an association with ustekinumab is at least a reasonable
possibility, that assessment would then result in changes to the ICF and/or the protocol consistent
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
64
Ap
proved, Date: 14 December 2020with assessment of the AE as an unanticipated problem and/or an adverse drug reaction to
ustekinumab. This assessment, as well as any resultant ICF or protocol changes, would promptly
be communicated to appropriate global health authorities and Ethics Committees/Institutional
Review Boards under whose auspi[INVESTIGATOR_485603].
The investigator (or sponsor where required) must report S[LOCATION_003]Rs consistent with the above to the
appropriate IEC/IRB that approved the protocol unless otherwise required and documented by [CONTACT_247919]/IRB. A S[LOCATION_003]R will be reported to regulatory authorities unblinded. Participating
investigators and IEC/IRB will receive a blinded S[LOCATION_003]R summary, unless otherwise specified.
Subjects will be provided with a "wallet (study) card" and instructed to carry this card with them
for the duration of the study indicating the following:
 Studynumber
 Statement, in the local language(s), that the subject is participating in a clinical study
 Investigator's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
 Local sponsor's name [CONTACT_3669] [CONTACT_23828] (for medical staff only)
 Site number
 Subject number
12.3.2. Serious Adverse Events
All SAEs occurring during the study must be reported to the appropriate sponsor contact [CONTACT_287058]-site personnel within [ADDRESS_623945] be completed and reviewed by a physician
from the study site, and transmitted to the sponsor within 24 hours. The initial and follow-up
reports of an SAE should be transmitted electronically or by [CONTACT_6972] (fax).
All SAEs that have not resolved by [CONTACT_2054], or that have not resolved upon
discontinuation of the subject's participation in the study, must be followed until any of the
following occurs:
 The event resolves
 The event stabilizes
 The event returns to baseline, if a baseline value/status is available
 The event can be attributed to agents other than the study drug or to factors unrelated to study
conduct
 It becomes unlikely that any additional information can be obtained (subject or health care
practitioner refusal to provide additional information, lost to follow-up after demonstration of
due diligence with follow-up efforts)
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
65
Ap
proved, Date: [ADDRESS_623946] will be reported as an SAE.
Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occurs during the
course of a subject's participation in a study must be reported as an SAE, except hospi[INVESTIGATOR_485604]:
 Hospi[INVESTIGATOR_43717] (eg, social reasons such as pending
placement in long-term care facility)
 Surgery or procedure planned before entry into the study (must be documented in the eCRF).
Note: Hospi[INVESTIGATOR_23743], and where the
underlying condition for which the hospi[INVESTIGATOR_23744], will not be
considered SAEs. Any AE that results in a prolongation of the originally planned
hospi[INVESTIGATOR_23745] a new SAE.
The cause of death of a subject in a study within [ADDRESS_623947] be reported to
the sponsor by [CONTACT_1758]-site personnel within 24 hours of their knowledge of the event using the
appropriate pregnancy notification form. Abnormal pregnancy outcomes (eg, spontaneous
abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs and
must be reported using the Serious Adverse Event Form. Any subject who becomes pregnant
during the study must discontinue further study treatment.
Female subjects of childbearing potential should not donate eggs during the study and for [ADDRESS_623948] administration of
study agent(s) in subjects participating in this clinical study must be reported by [CONTACT_485647] 12.3.2, Serious Adverse Events. Investigators are also
advised that active TB is considered a reportable disease in most countries. These events are to be
considered serious only if they meet the definition of an SAE.
12.4 . Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_485648](s), which will be provided as a separate document.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
66
Ap
proved, Date: [ADDRESS_623949] quality complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity, quality,
durability, or reliability of a product, including its labeling or package integrity. A PQC may have
an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and
analysis of PQC information from studies are crucial for the protection of subjects, investigators,
and the sponsor, and are mandated by [CONTACT_67819]. The sponsor has established
procedures in conformity with regulatory requirements worldwide to ensure appropriate reporting
of PQC information; all studies conducted by [CONTACT_70442].
13.1. Procedures
All initial PQCs must be reported to the sponsor by [CONTACT_1758]-site personnel within [ADDRESS_623950] report the
PQC to the sponsor according to the serious adverse event reporting timelines (refer to
Section 12.3.2, Serious Adverse Events). A sample of the suspected product should be maintained
for further investigation if requested by [CONTACT_456].
13.2. Contact[CONTACT_23834] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_485649](s), which will be
provided as a separate document.
14 . STUDY DRUG INFORMATION
14 .1. Physical Description of Study Drug(s)
The ustekinumab and ustekinumab placebo (for IV infusion) supplied for this study will be
manufactured and provided under the responsibility of the sponsor.
Ustekinumab for IV infusion will be supplied as a clear liquid containing 5 mg/mL per vial. Each
1 mL of ustekinumab solution contains 5 mg ustekinumab, L-histidine, L-histidine
monohydrochloride monohydrate, sucrose, L-methionine, Ethylenediaminetetraacetic acid
disodium salt dihydrate, and polysorbate 80 at pH 6.0. No preservatives are present.
Ustekinumab for SC injection will be supplied in a 90 mg/mL prefilled syringe (PFS). Each 1 mL
of ustekinumab solution in the PFS contains 90 mg ustekinumab, L-histidine, L-histidine
monohydrochloride monohydrate, sucrose, and polysorbate 80 at pH 6.0. No preservatives are
present.
Ustekinumab placebo for IV infusion is supplied as single-use, sterile solution in 30 mL vials with a
26 mL nominal volume. The composition of the placebo is 10 mM L-histidine, 8.5% (w/v) sucrose,
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
67
Ap
proved, Date: 14 December [ZIP_CODE].04% (w/v) polysorbate 80, 0.4 mg/mL L-methionine, and 20 µg/mL EDTA disodium salt
dihydrate at pH 6.0. No preservatives are present.
Ustekinumab placebo for SC injection will have the same appearance as the respective
ustekinumab administrations. Liquid placebo will also be supplied in a [ADDRESS_623951] a
composition 10 mM L-histidine, 8.5% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0. No
preservatives are present.
Adalimumab is manufactured by [CONTACT_485650]. Adalimumab is supplied as a liquid containing 40 mg/0.[ADDRESS_623952] kits. Each kit will contain enough study
drug for treatment q2w for 6 weeks (when given at Week 2) or 8 weeks (when given at each
subsequent visit).
The ustekinumab 5 mg/mL liquid formulation is intended for IV infusion after being diluted to an
appropriate concentration using an appropriate diluent.
Ustekinumab 90 mg/mL PFS is supplied as a single-use, sterile solution in a BD Hypak™ 1 mL,
type 1 glass syringe with a 27-gauge, 1/2-inch fixed needle. The needle cover on the PFS contains
dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals
sensitive to latex.
Adalimumab will be supplied as a PFS, purchased commercially by [CONTACT_456].
Study treatment will not be dispensed in child-resistant packaging. Blinded study treatment will
be administered by a qualified site personnel within an inpatient facility.
[ADDRESS_623953] be stored at controlled temperatures ranging from 36°F to 46°F (2°C to 8°C).
Refer to the pharmacy manual/study site investigational product and procedures manual for
additional guidance on study drug preparation, handling, and storage.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
68
Ap
proved, Date: [ADDRESS_623954] (if applicable), must be documented on the drug
accountability form. If required per local regulations, subjects must be instructed to return all
original containers, whether empty or containing study drug. All study drug will be stored and
disposed of according to the sponsor's instructions. Study-site personnel must not combine
contents of the study drug containers.
Study drug must be handled in strict accordance with the protocol and the container label, and
must be stored at the study site in a limited-access area or in a locked cabinet under appropriate
environmental conditions. Since subjects will be self-administering study drug at home between
Weeks [ADDRESS_623955] also be disposed of in the sharps container in order to
maintain the blind at the study site. Subjects will be instructed to return the sharps container and/or
cartons. Subjects will record study drug administrations with time and date information in the
subject Diary.
Potentially hazardous materials such as used ampules, needles, syringes and vials containing
hazardous liquids, should be disposed of immediately in a safe manner and therefore will not be
retained for drug accountability purposes.
Study drug should be dispensed under the supervision of the investigator or a qualified member of
the study-site personnel, or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study drug will be supplied only to
subjects participating in the study. Returned study drug must not be dispensed again, even to the
same subject. Study drug may not be relabeled or reassigned for use by [CONTACT_23837]. The
investigator agrees neither to dispense the study drug from, nor store it at, any site other than the
study sites agreed upon with the sponsor.
15. STUDY-SPECIFIC MATERIALS
The investigator will be provided with the following supplies:
 IB for ustekinumab
 Local prescribing information for adalimumab
 Pharmacy manual/study site investigational product and procedures manual
 Laboratory manual(s)
 PRO questionnaires and PRO completion guidelines
 IWRS Manual
 Electronic data capture (eDC) Manual
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
69
Ap
proved, Date: 14 December 2020 Sample ICF or Information Sheet (as applicable per country)
 Subject diaries
16. ETHICAL ASPECTS
16.1. Study-Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study and, during the
study, subjects will be given any new information that may affect their decision to continue
participation. They will be told that their consent to participate in the study is voluntary and may
be withdrawn at any time with no reason given and without penalty or loss of benefits to which
they would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits,
and potential adverse events of the study, and provide their consent voluntarily will be enrolled.
The total blood volume to be collected from each study participant will not exceed [ADDRESS_623956] limit for
whole blood donation (approximately 475 mL every 8 weeks) and is, therefore, considered an
acceptable amount of blood to be collected over this time period.2
16.2. Regulatory Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study is performed in accordance with the
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory and
country-specific requirements.
Good Clinical Practice is an international ethical and scientific quality standard for designing,
conducting, recording, and reporting studies that involve the participation of human subjects.
Compliance with this standard provides public assurance that the rights, safety, and well-being of
study subjects are protected, consistent with the principles that originated in the Declaration of
Helsinki, and that the study data are credible.
16.2.2. Independent Ethics Committee or Institutional Review Board
Before the start of the study, the investigator (or sponsor where required) will provide the IEC/IRB
with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_427]):
 Final protocol and, if applicable, amendments
 Sponsor-approved ICF (and any other written materials to be provided to the subjects)
 New edition(s) of the IB for ustekinumab and local prescribing information for adalimumab
 Sponsor-approved subject recruiting materials
 Information on compensation for study-related injuries or payment to subjects for
participation in the study, if applicable
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
70
Ap
proved, Date: 14 December 2020 Investigator's curriculum vitae or equivalent information (unless not required, as documented
by [CONTACT_6179]/IRB)
 Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential
conflicts of interest, and incentives for subjects
 Any other documents that the IEC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/IRB has given full approval of the final protocol,
amendments (if any, excluding the ones that are purely administrative, with no consequences for
subjects, data or study conduct, unless required locally), the ICF, applicable recruiting materials,
and subject compensation programs, and the sponsor has received a copy of this approval. This
approval letter must be dated and must clearly identify the IEC/IRB and the documents being
approved.
During the study the investigator (or sponsor where required) will send the following documents
and updates to the IEC/IRB for their review and approval, where appropriate:
 Protocol amendments (excluding the ones that are purely administrative, with no
consequences for subjects, data or study conduct)
 Revision(s) to ICF and any other written materials to be provided to subjects
 If applicable, new or revised subject recruiting materials approved by [CONTACT_456]
 Revisions to compensation for study-related injuries or payment to subjects for participation
in the study, if applicable
 New edition(s) of the IB for ustekinumab and local prescribing information for adalimumab
 Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at
least annually)
 Reports of adverse events that are serious, unlisted/unexpected, and associated with the study
drug
 New information that may adversely affect the safety of the subjects or the conduct of the
study
 Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
 Report of deaths of subjects under the investigator's care
 Notification if a new investigator is responsible for the study at the site
 Development Safety Update Report and Line Listings, where applicable
 Any other requirements of the IEC/IRB
For all protocol amendments (excluding the ones that are purely administrative, with no
consequences for subjects, data or study conduct), the amendment and applicable ICF revisions
must be submitted promptly to the IEC/IRB for review and approval before implementation of the
change(s).
At leastonce a year, the IEC/IRB will be asked to review and reapprove this study, where required.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
71
Ap
proved, Date: 14 December 2020At the end of the study, the investigator (or sponsor where required) will notify the IEC/IRB about
the study completion (if applicable, the notification will be submitted through the head of
investigational institution).
16.2.3. Informed Consent
Each subjectmust give written consent according to local requirements after the nature of the study
has been fully explained. The ICF(s) must be signed before performance of any study-related
activity. The ICF(s) that is/are used must be approved by [CONTACT_160231]/IRB and be in a language that the subject can read and understand. The informed consent
should be in accordance with principles that originated in the Declaration of Helsinki, current ICH
and GCP guidelines, applicable regulatory requirements, and sponsor policy.
Before enrollment in the study, the investigator or an authorized member of the study-site
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits,
and potential hazards of the study, and any discomfort participation in the study may entail.
Subjects will be informed that their participation is voluntary and that they may withdraw consent
to participate at any time. They will be informed that choosing not to participate will not affect the
care the subject will receive for the treatment of his or her disease. Finally, they will be told that
the investigator will maintain a subject identification register for the purposes of long-term follow
up if needed and that their records may be accessed by [CONTACT_485651], to the extent permitted by [CONTACT_478073](s) or regulations. By [CONTACT_485652], which
includes permission to obtain information about his or her survival status. It also denotes that the
subject agrees to allow his or her study physician to recontact [CONTACT_485653], and subsequent disease-related treatments, if
needed. The physician may also recontact [CONTACT_485654].
The subjectwill be given sufficient time to read the ICF and the opportunity to ask questions. After
this explanation and before entry into the study, consent should be appropriately recorded by
[CONTACT_19720]'s personally dated signature. After having obtained the consent, a copy of the
ICF must be given to the subject.
16.2.[ADDRESS_623957].
Sponsor personnel whose responsibilities require access to personal data agree to keep the identity
of subjects confidential.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
72
Ap
proved, Date: [ADDRESS_623958] includes explicit consent for the processing of
personal data and for the investigator/institutionto allow direct access to his or her original medical
records (source data/documents) for study-related monitoring, audit, IEC/IRB review, and
regulatory inspection. This consent also addresses the transfer of the data to other entities and to
other countries.
The subject has the right to request through the investigator access to his or her personal data and
the right to request rectification of any data that are not correct or complete. Reasonable steps will
be taken to respond to such a request, taking into consideration the nature of the request, the
conditions of the study, and the applicable laws and regulations.
16.2.5. Long-Term Retention of Samples for Additional Future Research
Samples collected in this study may be stored for up to 15 years (or according to local regulations)
for additional research. Samples will only be used to understand ustekinumab and adalimumab, to
understand differential drug responders, and to develop tests/assays related to ustekinumab or
adalimumabandCD. The research may begin at any time during the study or the post-study storage
period.
Stored samples will be coded throughout the sample storage and analysis process and will not be
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be
stored for research.
16.2.6. Country Selection
This study will only be conducted in those countries where the intent is to launch or otherwise help
ensure access to the developed product if the need for the product persists, unless explicitly
addressed as a specific ethical consideration in Section 16.1, Study-Specific Design
Considerations.
17. ADMINISTRATIVE REQUIREMENTS
17.1. Protocol Amendments
Neither the investigator nor the sponsor will modify this protocol without a formal amendment by
[CONTACT_456]. All protocol amendments must be issued by [CONTACT_456], and signed and dated by [CONTACT_31035]. Protocol amendments must not be implemented without prior IEC/IRB approval, or
when the relevant competent authority has raised any grounds for non-acceptance, except when
necessary to eliminate immediate hazards to the subjects, in which case the amendment must be
promptly submitted to the IEC/IRB and relevant competent authority. Documentation of
amendment approval by [CONTACT_23846]/IRB must be provided to the sponsor. When the
change(s) involves only logistic or administrative aspects of the study, the IEC/IRB (where
required) only needs to be notified.
During the course of the study, in situations where a departure from the protocol is unavoidable,
the investigator or other physician in attendance will contact [CONTACT_328024](s), which will be provided as a separate document. Except
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
73
Ap
proved, Date: [ADDRESS_623959] any departure from the protocol, and the source documents will describe
this departure and the circumstances requiring it.
17.2. Regulatory Documentation
17.2.1. Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory authorities
in each respective country, if applicable. A study may not be initiated until all local regulatory
requirements are met.
17.2.2. Required Prestudy Documentation
The following documents must be provided to the sponsor before shipment of study drug to the
study site:
 Protocol and amendment(s), if any, signed and dated by [CONTACT_458]
 A copy of the dated and signed (or sealed, where appropriate per local regulations), written
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if
applicable, subject compensation programs. This approval must clearly identify the specific
protocol by [CONTACT_23850] (or sealed, where appropriate per local
regulations) by [CONTACT_23851].
 Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and their
function, with a statement that it is organized and operates according to GCP and the
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from
the IEC/IRB, a general statement may be substituted for this list. If an investigator or a
member of the study-site personnel is a member of the IEC/IRB, documentation must be
obtained to state that this person did not participate in the deliberations or in the vote/opi[INVESTIGATOR_70362].
 Regulatory authority approval or notification, if applicable
 Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
 Documentation of investigator qualifications (eg, curriculum vitae)
 Completed investigator financial disclosure form from the principal investigator, where
required
 Signed and dated clinical trial agreement, which includes the financial agreement
 Any other documentation required by [CONTACT_43782]:
 Completed investigator financial disclosure forms from all subinvestigators
 Documentation of subinvestigator qualifications (eg, curriculum vitae)
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
74
Ap
proved, Date: 14 December 2020 Local laboratory documentation demonstrating competence and test reliability
(eg, accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy
identification of each subject during and after the study. This document will be reviewed by [CONTACT_70408]-site contact [CONTACT_23853].
The subject identification and enrollment log will be treated as confidential and will be filed by
[CONTACT_70409]. To ensure subject confidentiality, no copy will be made. All
reports and communications relating to the study will identify subjects by [CONTACT_70410]. In cases where the subject is not randomized into the study,
the date seen and age at initial informed consent will be used.
The investigator must also complete a subject screening log, which reports on all subjects who
were seen to determine eligibility for inclusion in the study.
17.[ADDRESS_623960] be available for the following:
subject identification, eligibility, and study identification; study discussion and date of signed
informed consent; dates of visits; results of safety and efficacy parameters as required by [CONTACT_70465]; record of all adverse events and follow-up of adverse events; concomitant medication;
drug receipt/dispensing/return records; study drug administration information; and date of study
completion and reason for early discontinuation of study drug or withdrawal from the study, if
applicable.
The author of an entry in the source documents should be identifiable.
Specific details required as source data for the study and source data collection methods will be
reviewed with the investigator before the study and will be described in the monitoring guidelines
(or other equivalent document).
The minimum source documentation requirements for Section 4.1, Inclusion Criteria and
Section 4.2, Exclusion Criteria that specify a need for documented medical history are as follows:
 Referral letter from treating physician or
 Complete history of medical notes at the site
 Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a
minimum by [CONTACT_41047] (eg, physical examination,
laboratory assessment) and documented in the source documents.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
75
Ap
proved, Date: [ADDRESS_623961] to document medical care (eg, electronic source documents) as well as the
clinical study-specific data fields as determined by [CONTACT_760]. This data is electronically
extracted for use by [CONTACT_456]. If the electronic source system is utilized, references made to the
CRF in the protocol include the electronic source system but information collected through the
electronic source system may not be limited to that found in the CRF. Data in this system may be
considered source documentation.
17.5. Case Report Form Completion
Case report forms (CRFs) are prepared and provided by [CONTACT_70463]. All CRF entries, corrections, and alterations must be made by [CONTACT_485655]-site personnel. The investigator must verify that all data entries in the CRF are accurate and
correct.
The study data will be transcribed by [CONTACT_3449]-site personnel from the source documents onto an
electronic CRF, if applicable.  Study-specific data will be transmitted in a secure manner to the
sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any
such worksheets will become part of the subject's source documents. Data must be entered into
CRF in English. The CRF must be completed as soon as possible after a subject visit and the forms
should be available for review at the next scheduled monitoring visit.
All patientive measurements (eg, questionnaires) will be completed by [CONTACT_328029].
If necessary, queries will be generated in the eDC tool. If corrections to a CRF are needed after
the initial entry into the CRF, this can be done in either of the following ways:
 Investigator and study-site personnel can make corrections in the eDC tool at their own
initiative or as a response to an auto query (generated by [CONTACT_66832]).
 Sponsor or sponsor delegate can generate a query for resolution by [CONTACT_70449]-
site personnel.
17.6. Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy and reliability of data include the selection of qualified
investigators and appropriate study sites, review of protocol procedures with the investigator and
study-site personnel before the study, and periodic monitoring visits by [CONTACT_456], and direct
transmission of clinical laboratory data and video ileocolonoscopy from a central vendor into the
sponsor's data base. Written instructions will be provided for collection, handling, storage, and
shipment of samples.
Guidelines for CRF completion will be provided and reviewed with study-site personnel before
the start of the study.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
76
Ap
proved, Date: 14 December 2020The sponsor will review CRF for accuracy and completeness during on-site monitoring visits and
after transmission to the sponsor; any discrepancies will be resolved with the investigator or
designee, as appropriate. After upload of the data into the study database they will be verified for
accuracy and consistency with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRF and
all source documents that support the data collected from each subject, as well as all study
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a Clinical
Trial, and all study documents as specified by [CONTACT_8146](s). The
investigator/institution will take measures to prevent accidental or premature destruction of these
documents.
Essential documents must be retained until at least [ADDRESS_623962]. These documents will be retained for a longer period
if required by [CONTACT_70469]. It is the
responsibility of the sponsor to inform the investigator/institution as to when these documents no
longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the
responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will accept
the responsibility. The sponsor must be notified in writing of the name [CONTACT_70497]. Under no circumstance shall the investigator relocate or dispose of any study documents
before having obtained written approval from the sponsor.
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any
documentation relating to this study, the investigator/institutionmust permit access to such reports.
17.8. Monitoring
The sponsor will use a combination of monitoring techniques (central, remote, or on-site
monitoring) to monitor this study.
The sponsor will perform on-site monitoring visits as frequently as necessary. The monitor will
record dates of the visits in a study site visit log that will be kept at the study site. The first post-
initiation visit will be made per the study monitoring plan. At these visits, the monitor will compare
data entered into the CRF with the source documents(eg, hospi[INVESTIGATOR_307]/clinic/physician’s office medical
records); a sample may be reviewed. The nature and location of all source documents will be
identified to ensure that all sources oforiginal data required to complete the CRF are known to the
sponsor and study-site personnel and are accessible for verification by [CONTACT_43786]-site
contact. If electronic records are maintained at the study site, the method of verification must be
discussed with the study-site personnel.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
77
Ap
proved, Date: [ADDRESS_623963] access to source documents (medical records) must be allowed for the purpose of verifying
that the recorded data are consistent with the original source data. Findings from this review will
be discussed with the study-site personnel. The sponsor expects that, during monitoring visits, the
relevant study-site personnel will be available, the source documents will be accessible, and a
suitable environment will be provided for review of study-related documents. The monitor will
meet with the investigator on a regular basis during the study to provide feedback on the study
conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during these
remote contacts, study-site personnel will be available to provide an update on the progress of the
study at the site.
17.9. Study Completion/Termination
17.9.1. Study Completion/End of Study
The study is considered completed with the last contact [CONTACT_485656]. The final data from the study site will be sent to the sponsor (or designee) after completion
of the final subject contact [CONTACT_485657], in the time frame specified in the Clinical Trial
Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study at any time for any
reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A
studysite is considered closed when all required documents and study supplies have been collected
and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause and
sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a studysite by [CONTACT_70470]:
 Failure of the investigator to comply with the protocol, the requirements of the IEC/IRB or
local health authorities, the sponsor's procedures, or GCP guidelines
 Inadequate recruitment of subjects by [CONTACT_093]
 Discontinuation of further study drug development
17.10. On-Site Audits
Representatives of the sponsor's clinical quality assurance department may visit the study site at
any time during or after completion of the study to conduct an audit of the study in compliance
with regulatory guidelines and company policy. These audits will require access to all study
records, including source documents, for inspection. Subject privacy must, however, be respected.
The investigator and study-site personnel are responsible for being present and available for
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
78
Ap
proved, Date: 14 December 2020consultation during routinely scheduled study-site audit visits conducted by [CONTACT_70468].
Similar auditing procedures may also be conducted by [CONTACT_67840], either as part
of a national GCP compliance program or to review the results of this study in support of a
regulatory submission. The investigator should immediately notify the sponsor if he or she has
been contact[CONTACT_426] a regulatory agency concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding ustekinumab or the sponsor's
operations (eg, patent application, formulas, manufacturing processes, basic scientific data, prior
clinical data, formulation information) supplied by [CONTACT_70460], and any data generated as a result of this study, are considered confidential
and remain the sole property of the sponsor. The investigator agrees to maintain this information
in confidence and use this information only to accomplish this study, and will not use it for other
purposes without the sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_485658], and thus may be disclosed
as required to other clinical investigators or regulatory agencies. To permit the information derived
from the clinical studies to be used, the investigator is obligated to provide the sponsor with all
data obtained in the study.
The results of the study will be reported in a Clinical Study Report generated by [CONTACT_70462]. Recruitment
performance or specific expertise related to the nature and the key assessment parameters of the
study will be used to determine a coordinating investigator. Study subject identifiers will not be
used in publication of results. Any work created in connection with performance of the study and
contained in the data that can benefit from copyright protection (except any publication by [CONTACT_485659]) shall be the property of the sponsor as author and owner of
copyright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal
Editors guidelines, the sponsor shall have the right to publish such primary (multicenter) data and
information without approval from the investigator. The investigator has the right to publish study
site-specific data after the primary data are published. If an investigator wishes to publish
information from the study, a copy of the manuscript must be provided to the sponsor for review
at least [ADDRESS_623964] been published. Similarly, investigators
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
79
Ap
proved, Date: [ADDRESS_623965] been
submitted for publication, within 12 months of the availability of the final data (tables, listings,
graphs), or the sponsor confirms there will be no multicenter study publication. Authorship of
publications resulting from this study will be based on the guidelines on authorship, such as those
described in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, which
state that the named authors must have made a significant contribution to the design of the study
or analysis and interpretation of the data, provided critical review of the paper, and given final
approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as required
by [CONTACT_2371].
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
80
Approv e
d, Date: 14 December 2020REFERENCES
1. Ali T, Madhoun MF, Orr WC, et al. Assessment of the relationship between quality of sleep and disease
activity in inflammatory bowel disease patients. Inflamm Bowel Dis 2013;19:2440-2443.
2. American Red Cross. Blood donation information website. http://www.redcrossblood.org/learn-about
blood/blood-facts-and-statistics. Accessed 20 November 2017.
3. Anathakrishnan AN, Long MD, Martin CF, et al. Sleep disturbance and risk of active disease in patients with
Crohn’s disease and ulcerative colitis. Clin Gastroenterol Hepatol 2013;11:965-971.
4. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National
Cooperative Crohn’s Disease Study. Gastroenterology 1976;70:439-444.
5. Cella D, Riley W, Stone A, et al, on behalf of the PROMIS Cooperative Group. The Patient-Reported
Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-
reported health outcome item banks. J Clin Epi[INVESTIGATOR_5541] 2010;63:1179-1194.
6. Colombel JF, Sandborn WJ, Reinisch W, et al. for the SONIC study group. Infliximab, azathioprine, or
combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383-1395.
7. Colombel JF, Sandborn WJ, Rutgeerts P. Adalimumab for maintenance of clinical response and remission in
patients with Crohn’s disease: The CHARM Trial. Gastroenterology 2007;132:52–65.
8. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel
Dis 2002;8:244-250.
9. D’Incà R, Caccaro R. Measuring disease activity in Crohn’s disease: what is currently available to the
clinician. Clin Exp Gastroenterol 2014;7:151–161.
10. Feagan BG, Sandborn WJ, Gasink C, et al, for the UNITI–IM-UNITI Study Group. Ustekinumab as Induction
and Maintenance Therapy for Crohn’s Disease. N Engl J Med 2016; 375:1946-1960.
11. Frolkis AD, Dykeman J, Negron ME, et al. Risk of surgery for inflammatory bowel diseases has decreased
over time: A systematic review and meta-analysis of population-based studies. Gastroenterology
2013;145:996– 100
6.
12. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody
(Adalimumab) in Crohn’s disease: the CLASSIC-I Trial. Gastroenterology 2006;130:323–333.
13. http://www.shelby[CONTACT_485660].com/Forms/Pre-treatment%20symptom%20profile.pdf ; last accessed 10/17/2017.
14. https://view.officeapps.live.com/op/view.aspx?src=http%3A%2F%2Fwww.reillyassociates.net%2FEnglish-
[LOCATION_006]-WPAI-CD-eDiary-.doc;  last accessed 7/26/2017.
15. Humira® (adalimumab) package insert, North Chicago, IL: [COMPANY_013] Inc.; 2017
16. Irvine EJ, Feagan B, Rochon J, et al. Quality of life:  a valid and reliable measure of therapeutic efficacy in the
treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group.
Gastroenterology 1994;106:287-296.
17. Mao EJ, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: Comparative efficacy of
immunosuppressants and biologics for reducing hospi[INVESTIGATOR_485605]'s disease and ulcerative
colitis. Aliment Pharmacol Ther. 2017;45:3-13.
18. Panaccione R, Ghosh S. Optimal use of biologics in the management of Crohn’s disease. Ther Adv
Gastroenterol 2010;3:179-189.
19. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease:
results of the CLASSIC II trial. Gut 2007;56:1232-1239.
20. Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial:
increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J
Crohn’s Colitis 2013;7:213-221.
21. Stelara® (ustekinumab) package insert. Horsham, PA: Janssen Research and Development; 2017.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
81
Ap
proved, Date: [ADDRESS_623966], Papandony MC, Gibson PR. Sleep and physical activity measured by [CONTACT_485661]’s disease. Aliment Pharmacol Ther 2015;41:991-1004.
23. Vergara-Gomez M, Montserrat A, Casellas F. Clinical outcomes assessment:  A new validation of the Spanish
Work Productivity and Activity Impairment Questionnaire—Crohn’s Disease Version. Value in Health.
2011:859 – 861. Published by [CONTACT_342323].  doi:10.1016/j.jval.2011.02.1179
24. Yanai H, Hanauer S. Assessing response and loss of response to biological therapi[INVESTIGATOR_485606]. Am J
Gastroenterol 2011;106:685-698
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
82
Ap
proved, Date: 14 December 2020ATTACHMENT 1: SAMPLE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE
(IBDQ)
Copyright © 1989 McMaster University, Hamilton, Ontario, Canada
The Inflammatory Bowel Disease Questionnaire (IBDQ), authored by [INVESTIGATOR_124]. Jan Irvine et al, is the copyright of
McMaster University (Copyright ©1989, McMaster University).  The IBDQ has been provided under license
from McMaster University and must not be copi[INVESTIGATOR_530], distributed or used in any way without the prior written
consent of McMaster University.  Contact [CONTACT_485662],
email: [EMAIL_7550] for licensing details.
Updated from: IBDQ - [LOCATION_008]-Englis h - Vers ion of 09 May 08 - Mapi [INVESTIGATOR_485607].
ID4529/IBDQ_AU2.0_eng-GB.doc
IBDQ (enGB)  03JUN2016 FINAL –ICON Language Services
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
83
Ap
proved, Date: 14 December 2020INSTRUCTIONS FOR SELF-ADMINISTERED INFLAMMATORY BOWEL
DISE
ASE QUESTIONNAIRE (IBDQ)
This
 ques tionnaire is  des igned to meas ure the effects  of your inflammatory
bowel dis eas e on your daily function and quality of life. You will be as ked about
s ymptoms  you have been having as  a res ult of your bowel dis eas e,the way you
have been feeling in general, and how your mood has  been.
There are two vers ions  of this  ques tionnaire, the IBDQ and IBDQ-Stoma. If
you have a colos tomy or ileos tomy, you s hould complete the IBDQ-Stoma.
Ques tions  1, 5, 17, 22, [ADDRESS_623967] 2 weeks?
[ADDRESS_623968] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
If you are having trouble unders tanding a ques tion, STOP for a moment!
Think about what the ques tion means  to you. How is  it affected by [CONTACT_485663]? Then ans wer the ques tion as  bes t you can. You will have the chance to
as k the res earch as s is tant ques tions  after completing the ques tionnaire. This
takes  only a few minutes  to complete.
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
84
Ap
proved, Date: 14 December 2020QUALITY OF LIFE IN INFLAMMATORY BOWEL DIS EASE QUESTIONNAIRE (IBDQ)
This questionnaire is designed to find out how you have been feeling during the
last [ADDRESS_623969] your bowel movements  been during the las t two weeks ? Pleas e
indicate how frequent your bowel movements  have been during the las t two weeks  by
[CONTACT_21173][INVESTIGATOR_485608]
[ADDRESS_623970] EVER EXPERIENCED
2 EXTREMELY FREQUENT
3 VERY FREQUENT
4 MODERATE INCREASE IN FREQUENCY OF BOWEL MOVEMENTS
5 SOME INCREASE IN FREQUENCY OF BOWEL MOVEMENTS
6 SLIGHT INCREASE IN FREQUENCY OF BOWEL MOVEMENTS
7 NORMAL, NO INCREASE IN FREQUENCY OF BOWEL MOVEMENTS
2. How often has  the feeling of fatigue or of being tired and worn out been a problem for you
during the las t 2 weeks ? Pleas e indicate how often the feeling of fatigue or tirednes s  has
been a problem for you during the las t [ADDRESS_623971] you felt frus trated, impatient or res tles s ?  Pleas e
choos e an option from
[ADDRESS_623972] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
85
Ap
proved, Date: [ADDRESS_623973] you been unable to attend s chool or do your work
becaus e of your bowel problem? Pleas e choos e an option from
[ADDRESS_623974] your bowel movements  been loos e?
Pleas e choos e an option from
[ADDRESS_623975] you had during the las t 2 weeks ? Pleas e choos e an option from
[ADDRESS_623976] s urgery becaus e of your bowel problem?  Pleas e choos e an option from
[ADDRESS_623977] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
86
Ap
proved, Date: [ADDRESS_623978] you had to delay or cancel a s ocial engagement
becaus e of your bowel problem? Pleas e choos e an option from
[ADDRESS_623979] you been troubled by [CONTACT_485664]?
Pleas e choos e an option from
[ADDRESS_623980] you felt generally unwell?  Pleas e choos e an
option from
[ADDRESS_623981] you been troubled becaus e of fear of not finding
a toilet? Pleas e choos e an option from
[ADDRESS_623982] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
87
Ap
proved, Date: [ADDRESS_623983] done during the las t 2 weeks ? Pleas e
choos e an option from
1 A GREAT DEAL OF DIFFICULTY; ACTIVITIES MADE IMPOSSIBLE
2 A LOT OF DIFFICULTY
3 A FAIR BIT OF DIFFICULTY
4 SOME DIFFICULTY
5 A LITTLE DIFFICULTY
6 HARDLY ANY DIFFICULTY
7 NO DIFFICULTY; THE BOWEL PROBLEMS DID NOT LIMIT SPORTS OR LEISURE
ACTIVITIES
13. How often during the las t [ADDRESS_623984] you been troubled by [CONTACT_393415]?
Pleas e choos e an option from
[ADDRESS_623985] you had problems  getting a good night’s  s leep or
been troubled by [CONTACT_212964]? Pleas e choos e an option from
[ADDRESS_623986] you felt depres s ed or dis couraged? Pleas e choos e
an option from
[ADDRESS_623987] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
88
Ap
proved, Date: [ADDRESS_623988] you had to avoid attending events  where there
was  no toilet clos e at hand? Pleas e choos e an option from
[ADDRESS_623989] you had with pas s ing large
amounts  of wind? Pleas e choos e an option from
[ADDRESS_623990] you had maintaining or getting
to the weight you would like to be at? Pleas e choos e an option from
[ADDRESS_623991] you
felt worried or anxious ? Pleas e choos e an option from
[ADDRESS_623992] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
89
Ap
proved, Date: [ADDRESS_623993] you been troubled by a feeling of
abdominal bloating? Pleas e choos e an option from
[ADDRESS_623994] you felt relaxed and free of tens ion?  Pleas e
choos e an option from
[ADDRESS_623995] you had a problem with rectal bleeding
with your bowel movements ? Pleas e choos e an option from
[ADDRESS_623996] you felt embarras s ed as  a res ult of
your bowel problem? Pleas e choos e an option from
[ADDRESS_623997] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
90
Ap
proved, Date: [ADDRESS_623998] you been troubled by a feeling of
having to go to the toilet even though your bowelswere empty?  Pleas e choos e an option
from
[ADDRESS_623999] you felt tearful or ups et?  Pleas e
choos e an option from
[ADDRESS_624000] you been troubled by [CONTACT_485665] s oiling
of your underpants ? Pleas e choos e an option from
[ADDRESS_624001] you felt angry as  a res ult of your bowel
problem? Pleas e choos e an option from
[ADDRESS_624002] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
91
Ap
proved, Date: 14 December 202028. To what extent has  your bowel problem limited s exual activity during the las t 2 weeks ?
Ple
as e choos e an option from
[ADDRESS_624003] you been troubled by [CONTACT_485666] s tomach? Pleas e choos e an option from
[ADDRESS_624004] you felt irritable?  Pleas e choos e an
option from
[ADDRESS_624005] you felt a lack of unders tanding from others ? 
Pleas e choos e an option from
[ADDRESS_624006] OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
92
Ap
proved, Date: [ADDRESS_624007] you been with your pers onal life during the pas t 2
weeks ? Pleas e choos e one of the following options  from
[ADDRESS_624008] BEEN MORE HAPPY OR PLEASED
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
93
Ap
proved, Date: 14 December 2020ATTACHMENT 2:  SAMPLE PROMIS-29 QUESTIONNAIRE

Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
94
Ap
proved, Date: 14 December 2020

Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
95
Ap
proved, Date: 14 December 2020

Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
96
Ap
proved, Date: 14 December 2020ATTACHMENT 3: SAMPLE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT
QUESTIONNAIRE: CROHN’S DISEASE (WPAI-CD)
Work Productivity and Activity Impairment Questionnaire:
CROHN’S DISEASE (WPAI-CD)
The following ques tions  as k about the effect of your Crohn’s  dis eas e on your ability to
work and perform regular activities .  Please f ill in the blanks or circle a number, as
indicated.
1. Are you currently employed (working for pay) ?       _____NO  _____YES
If NO, check “ NO”  and skip to question 6.
The next ques tions  are about the past seven days , not including today.
2. During the pas t s even days , how many hours  did you mis s  from work becaus e of
problems  as s ociated with your Crohn’s  dis eas e?  Include hours you missed on sick
da
ys, times you went in late, left early, etc., because of  your Crohn’s disease.  Do
not include time you missed to participate in this study.
_____ HOURS
3. During the pas t s even days , how many hours  did you mis s  from work becaus e of
any other reas on, s uch as  vacation, holidays , time off to participate in this  s tudy?
_____HOURS
4. During the pas t s even days , how many hours  did you actually work?
_____HOURS (If “ 0” , skip to question 6.)
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
97
Ap
proved, Date: 14 December [ZIP_CODE]. During the pas t s even days , how much did your Crohn’s  dis eas e affect your
productivity while you were working?
Think
 about days  you were limited in the amount or kind of work you could do, days
you accomplis hed les s  than you would like, or days  you could not do your work as
carefully as  us ual.  If Crohn’s  dis eas e affected your work only a little, choos e a low
number.  Choos e a high number if Crohn’s  dis eas e affected your work a great deal.
Crohn’s
dis eas e had no
effect on my
workCrohn’s  dis eas e
completely
prevented me
from working0 [ADDRESS_624009]
CLE A NUMBER
6. During the pas t s even days , how much did your Crohn’s  dis eas e affect your ability
to do your regular daily activities , other than work at a job? 
By [CONTACT_43681], we mean the usual activities you do, such as work around the
house, shoppi[INVESTIGATOR_007], childcare, exercising, studying, etc.  T hink about times you were
limited in the amount or kind of activities you could do and times you accomplished
less than you would like.  If  Crohn’ s disease af f ected your activities only a little,
choose a low number.  Choose a high number if  Crohn’ s disease af fected your
activities a great deal.
Crohn’s
dis eas e had no
effect on my
daily activitiesCrohn’s  dis eas e
completely
prevented me
from doing my
daily activities0 [ADDRESS_624010]
CLE A NUMBER
Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
98
Ap
proved, Date: 14 December 2020ATTACHMENT 4 :  CROHN’S DISEASE ACTIVITY INDEX

Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
99
Ap
proved, Date: 14 December 2020ATTACHMENT 5:  STANDARD WEIGHT TABLE

Stelara® (ustekinumab); Humira® (adalimumab)
Clinical Protocol CNTO1275CRD3007 Amendment 2
100
Ap
proved, Date: [ADDRESS_624011] of the study, and the obligations of confidentiality.
Coordinating Investigator (where required):
Name (typed or printed):
Institution and Address:
Sig
nature: Date:
(D
ay Month Year)
Pr
incipal (Site) Investigator:
Name (typed or printed):
Institution and Address:
Te
lephone Number:
Sig
nature: Date:
(D
ay Month Year)
Spo
nsor's Responsible Medical Officer:
Name (typed or printed): Andrew Greenspan, MD
Institution: Janssen Research & Development
Sig
nature: [electronic signature [CONTACT_111203]] Date:
(D
ay Month Year)
Not
e: If the address or telephone number of the investigator changes during the course of the study, written
notification will be provided by [CONTACT_68477], and a protocol amendment will not be required.
Sign
ature
Use
r Da
te Re
ason
GR
EENSPAN ANDREW 194058 14-Dec-2020
 
21
:13:23
(GMT)Docum
ent Approval
Janssen Research & Development
Clinical trial CNTO1275CRD3007 (SEAVUE)
COVID -19: Measures taken for ongoing stud y
Amendment to CTA as part of Urgent Safety Measure
EudraCT numbers: 2017 -004209 -41
Status: Approved for Dossier Use
Date: 21 April 2020
Prepared by: [CONTACT_12945] & Development, LLC 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and 
may not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
informati on is disclosed must be informed that the information is privileged or confidential and may not be further disclosed 
by [CONTACT_476]. These restrictions on disclosure will apply equally to allfuture information supplied to you that is indicated as 
privileged or c onfidential .
[STUDY_ID_REMOVED]
CNTO1275CRD3007
Crohn’s Disease             
1.INTRODUCTION
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this clinical study , CNTO1275CRD3007 ,due to, for example, self-
isolation/quarantine by [CONTACT_124835] -site personnel; travel restrictions/limited access to 
public places, including hospi[INVESTIGATOR_600]; and/or study  site personnel being reassigned to critical tasks.
In alignment with recent health authority  guidance, the sponsor is providing options for study  
related patient management in the event of disruption to the conduct of the study . This guidance 
does not supersede any local or government requirements or the clinical judgement of the 
investigator to protect the health and well -being of patient and site staff. If, at any time, a patient’s 
safet y is considered to be at risk, study  intervention swill be discontinued or delay ed, and study  
follow -up will be conducte d. Asappropriate, impacted study  site Investigators will need to assess 
therisk of continuing the study  balanced with the risk of discontinuing study  agent.  A gap in 
active treatment may lead to a disease -flare. This could lead to disease progression aswell as a 
possible hospi[INVESTIGATOR_063]. Multiple professional societies , including the International 
Organization for the Study  of Inflammatory  Bowel Disease (IOIBD), United European 
Gastroenterology (UEG) ,and European Crohn’s and Colitis Organization (ECCO ),have advised 
all patients with inflammatory  bowel disease (IBD) to remain on current treatments, where 
possible ,given the risk of worsening disease if they are stopped (IOIBD 
https://www.gastrojournal.org/article/S0016 -5085(20)[ZIP_CODE] -0/fulltext ; Danese, et al, Management of IBD 
during the COVID -19 outbreak: resetting clinical priorities. Nature Reviews Gastroenterology  & 
Hepatology  [25 March 2020] ).  Notabl y, the study  protocol clearl y states (in Section 6 )that in the 
event of a clinically  import ant, active infection ,which COVID -19certainly  represents , all study 
treatment should be held until that infection clears and,that discontinuation of study  agent should 
be considered if patients develop a serious infection .
In light of COVID -19,the sponsor is now providing guidance to study  sites on potential 
modifications, provided they areconsistent with local regulations, patient privacy  practices, and 
areotherwise feasible . They  include remote study  visits, guidance on performing efficacy  and 
safet y assessments, study  agent dispensing alternatives (including direct to patient [DTP] 
shippi[INVESTIGATOR_007]), and the tracking of COVID -related protocol deviations that occur . Notabl y, for this 
study , the performance of remote visits and provision of study  drug directly  to patients are in 
alignment with the protocol , which does not stipulate the location of visits and refers to the study  
pharmacy  manual formechanism and methods of study  agent dispensing (protocol Section 7).  
However, theseoperational changes do represent urgent safety  measures (USM) , per regional (e.g., 
European Medicines Agency ) and local guidance , and may impact other related clinical trial 
application documents.  Study CNTO1275CRD3007 will continue under the currently  approved 
protocol with appropriate modifications as described below.  
1.1 STUDY BACKGROUND
CNTO1275CRD3007, A Phase 3b, Multicenter, Randomized, Blinded, Active -Controlled Study 
to Compare the Efficacy and Safet y of Ustekinumab to that of Adalimumab in the Treatment of 
Biologic Naïve Subjects with Moderately -to-Severel y Active Crohn’s Disease, also known as 
CNTO1275CRD3007
Crohn’s Disease             
SEAVUE ,is an ongoing study .  This one-year study  began in 2018 and completed enrollment in 
December 2019.  Patients are followed for 1 year; we anticipate completion of the primary  efficacy 
portion of the study , with a database lock when all patients complete their Week 52 primary 
endpoint ,at the end of 2020. 
As a Phase 3b study , SEAVUE is comparing approved medications (ustekinumab and 
adalimumab) using labelled dosing. Per protocol, patients are trained to inject themselves with 
study  agent andafter week 2, they self-administer the study agent at home .  Subsequent to week 
2, study visits are scheduled every  [ADDRESS_624012] 8 weeks ,therefore, 
per protocol, all patients are currentl yself-administering study  agent at home .
2.REMOTE STUDY VISITS
Given restrictions on travel and on -site visits, patients may  not be able to be seen at the study  site 
for evaluation.  Guidance is being provided to sites that remote study  visits can be performed by 
[CONTACT_756], or if possible, as a video telemedicine/tele health visit, provided this is consistent with 
local regulations, patient privacy  practices, and is otherwise feasible. Further, the possibility  to 
perform home health visits, and specific relevant guidance, is being explored. Sites arebeing 
provided guidance onbest practices for the collection of efficacy  and safet y data under these 
circumstances .  Adverse events (AE), serious AEs and concomitant medications will continue to 
be reported and documented ,per protocol, even during these modified visits .In addition, any 
deviations that result from assessments that cannot be performed remotely  (eg,physical 
examination for abdominal mass per the CDAI key efficacy  measure) will be captured (see Section 
4 below) .
Laboratory Studies
Local laboratory  studies may be performed if patients cannot come to the site, as a part of standard 
of care for safet y monitoring purposes . This is permitted per protocol, as approved b y the medical 
monitor, which has been granted during the COVID -19 pandemic . Any local laborator y result t hat 
represent s aclinically  relevant change, in the investigator’s opi[INVESTIGATOR_1649], should be reported as an 
Adverse Event.  Because l ocal lab oratory  results are not incorporated into the study  database they  
are not interchangeable with central laborator y results ,which should therefore be resumed as soon 
as conditions permit . In addition, for selected measures (eg ,urine pregnancy ), home testing may  
be employ ed.
3.DIRECT TO PATIENT SHIPMENT
In exceptional circumstances, other study  agent dispensing solutions may be considered by [CONTACT_37233], depending on the Health Authority ’s country  requirements, medical disease management, 
and the need to maintain protocol ‐specified treatment schedule . Spec ifically , DTP shippi[INVESTIGATOR_485609] a per -patient level with a written request to the sponsor.  Once a request is made, 
DTP processes will be initiated by [CONTACT_485667] (ie,World 
Courier) who will then manage the distribution of study  agent between the study  site and patient , 
including mandatory  temperature tracking for these products and traceability  of the transport .  
CNTO1275CRD3007
Crohn’s Disease             
As a part of this process ,all personal patient information remains confidential and is not disclosed 
to the sponsor. The sponsor will activate the courier and will provide the courier contacts to the 
study  site.  As such there will be direct communication between the study  site and courier and only 
the site communicates the patient’s details tothe courier.  The patient should verbally  consent to 
share home address with the courier for this purpose, which will be recorded in patient source 
records. The site must retain courier documentation, track the shipment and confirm successful 
delivery  to the patient. The site must maintain drug accountabilit y records.  
Full details describing the dispensing and distribution of study  agent are included in the Site 
Investigational Product Procedures Manual (SIPPM), which will be updated with these procedure s 
specific to the DTP process.  This information is only presented in the SIPPM and not described 
in the protocol. 
4.COVID -RELA TED DEVIA TIONS
Any missing data, including missed central laboratory  tests and assessments that cannot be 
performed remotely  (egphysical examination for abdominal mass per the CDAI key efficacy  
measure) ,will be documented as protocol deviations by [CONTACT_485668] -19,and tracked for future reporting and analy sis purposes. The occurrence of remote visits 
will also berecorded in the source document s. All COVI D-related deviations will be fully 
discussed in the CSR, including their potential impact on the study .
5.SITE MONITORING
With regards tosite monitoring visits atsites where these are not currently  allowed, Site Managers 
will perform remote monitoring with investigative staff, as allowed and appropriate . On-site 
monitoring, perstudy monitoring guidelines ,will be resumed when Site Managers are permitted
to return to the sites.
6.CONCLUSION/SUMMA RY
The sponsor is committed to theprotection of patient safety  in-light of the COVI D-[ADDRESS_624013] of COVID -19 on collection of key study data and additional 
data analyses will be outlined in study  Statistical Analy sis Plan (SAP). Further, the sponsor will 
continue to monitor the conduct and progress of the clinical study with respect to the COVID -19 
pandemic and anyadditional changes will be communicated to the sites and health authorities , as 
needed, according to local guidance.